{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:03:52Z","timestamp":1794589432487,"version":"4.9.1"},"reference-count":548,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer\u2019s disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson\u2019s disease dementia (PDD). The distinction between these two conditions lies in the timing of the onset of cognitive impairment relative to motor symptoms. In DLB, cognitive impairment precedes or coincides with motor symptoms within the first year, whereas in PDD, cognitive decline occurs more than a year after the onset of motor symptoms. Clinically, in addition to cognitive decline, patients with Lewy body dementia have parkinsonism, visual hallucinations, and fluctuations of cognitive status. The pathological hallmark of this condition is the presence of Lewy bodies and Lewy neurites, collectively referred to as Lewy-related pathology. This is identical to Parkinson\u2019s disease, where dementia is not observed. The principal component of Lewy-related pathology is \u03b1-synuclein, which classifies this disorder as an \u03b1-synucleinopathy. While Lewy-related pathology represents a later stage of \u03b1-synuclein aggregation, earlier stages involve \u03b1-synuclein oligomers. Emerging evidence suggests \u03b1-synuclein oligomers may be more toxic than Lewy-related pathology. In addition to \u03b1-synuclein pathology, previous studies frequently observed comorbid pathological conditions, including Alzheimer\u2019s disease neuropathologic change, TAR DNA-binding protein 43 (TDP-43) pathology, and cerebral small vessel disease among others. In this review, we provide a comprehensive overview of the underlying pathologies for Lewy body dementia and their molecular mechanisms and clinical implications. We also discuss concepts including the prion-like propagation hypothesis of \u03b1-synuclein, \u03b1-synuclein strain hypothesis, and recent advances in machine learning algorithms for analyzing propagation patterns. The purpose of this manuscript is to elucidate these complex pathological conditions, advance our understanding of the disease, and improve diagnostic strategies.<\/jats:p>","DOI":"10.1186\/s13024-025-00900-6","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:15:50Z","timestamp":1762168550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Neuropathology of Lewy body dementia: Lewy-related pathology, \u03b1-synuclein oligomers, and comorbid pathologies"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9683-5966","authenticated-orcid":false,"given":"Hiroaki","family":"Sekiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-8284","authenticated-orcid":false,"given":"Tomoyasu","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"DeTure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-7917","authenticated-orcid":false,"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"issue":"Suppl, 1","key":"900_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe W. Non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol. 2008;15(Suppl, 1):14\u201320.","journal-title":"Eur J Neurol"},{"key":"900_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","volume":"11","author":"P Svenningsson","year":"2012","unstructured":"Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson\u2019s disease: diagnosis, biomarkers, and treatment. The Lancet Neurol. 2012;11:697\u2013707.","journal-title":"The Lancet Neurol"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837\u201344.","journal-title":"Mov disord"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"900_CR6","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879\u201384.","journal-title":"Am J Pathol"},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"10422","DOI":"10.1038\/srep10422","volume":"5","author":"M Nors Perdersen","year":"2015","unstructured":"Nors Perdersen M, V F, Horvath I, van Maarschalkerweerd A, N\u00f8rgaard Toft, Weise C, Almqvist F, Wolf-Watz M, Wittung-Stafshede P, Vestergaard B. Direct correlation between ligand-induced \u03b1-Synuclein oligomers and amyloid-like fibril growth. Sci Rep. 2015;5:10422.","journal-title":"Sci Rep"},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam P, Bousset L, Melki R, Otzen DE. \u03b1-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem. 2019;150:522\u201334.","journal-title":"J NeuroChem"},{"key":"900_CR9","doi-asserted-by":"crossref","unstructured":"Ingelsson M. Alpha-Synuclein oligomers-neurotoxic molecules in Parkinson\u2019s disease and other Lewy body disorders. Front Neurosci. 2016;10:408.","DOI":"10.3389\/fnins.2016.00408"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","volume":"134","author":"N Bengoa-Vergniory","year":"2017","unstructured":"Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017;134:819\u201338.","journal-title":"Acta Neuropathol"},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.4103\/1673-5374.371345","volume":"18","author":"A Bigi","year":"2023","unstructured":"Bigi A, Cascella R, Cecchi C. \u03b1-synuclein oligomers and fibrils: partners in crime in synucleinopathies. Neural Regen Res. 2023;18:2332\u201342.","journal-title":"Neural Regen Res"},{"key":"900_CR12","first-page":"1234","volume":"90","author":"C Smith","year":"2019","unstructured":"Smith C, Malek N, Grosset K, Cullen B, Gentleman S, Grosset DG. Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies. J Neurol Neurosurg Psychiatry. 2019;90:1234\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1212\/CON.0000000000001137","volume":"28","author":"JA Schneider","year":"2022","unstructured":"Schneider JA. Neuropathology of dementia disorders. Continuum (minneap Minn). 2022;28:834\u201351.","journal-title":"Continuum (minneap Minn)"},{"key":"900_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/alz.12814","volume":"19","author":"JB Toledo","year":"2023","unstructured":"Toledo JB, Abdelnour C, Weil RS, Ferreira D, Rodriguez-Porcel F, Pilotto A, Wyman-Chick KA, Grothe MJ, Kane JPM, Taylor A, et al. Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design. Alzheimers Dement. 2023;19:318\u201332.","journal-title":"Alzheimers DeMent"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaneurol.2023.3664","volume":"80","author":"RC Petersen","year":"2023","unstructured":"Petersen RC, Weintraub S, Sabbagh M, Karlawish J, Adler CH, Dilworth-Anderson P, Frank L, Huling Hummel C, Taylor A. A new framework for dementia nomenclature. JAMA Neurol. 2023;80:1364\u201370.","journal-title":"JAMA Neurol"},{"key":"900_CR16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"AP Association","year":"2013","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychi Assoc. 2013."},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","volume":"7","author":"M Goedert","year":"2017","unstructured":"Goedert M, Jakes R, Spillantini MG. The synucleinopathies: twenty years on. J Parkinsons Dis. 2017;7:S51\u2013s69.","journal-title":"J Parkinsons Dis"},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1750-3639.1999.tb00553.x","volume":"9","author":"DW Dickson","year":"1999","unstructured":"Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999;9:721\u201332.","journal-title":"Brain Pathol"},{"key":"900_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2990.2007.00907.x","volume":"33","author":"JQ Trojanowski","year":"2007","unstructured":"Trojanowski JQ. Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. 2007;33:615\u201320.","journal-title":"Neuropathol Appl neurobiol"},{"key":"900_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0022-510X(89)90219-0","volume":"94","author":"MI Papp","year":"1989","unstructured":"Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and shy-drager syndrome). J Neurol Sci. 1989;94:79\u2013100.","journal-title":"J Neurol Sci"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1093\/brain\/awv114","volume":"138","author":"MD Cykowski","year":"2015","unstructured":"Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, Schmeichel AM, Parisi JE. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138:2293\u2013309.","journal-title":"Brain"},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00401-019-01961-w","volume":"137","author":"H Sekiya","year":"2019","unstructured":"Sekiya H, Kowa H, Koga H, Takata M, Satake W, Futamura N, Funakawa I, Jinnai K, Takahashi M, Kondo T, et al. Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol. 2019;137:455\u201366.","journal-title":"Acta Neuropathol"},{"key":"900_CR23","doi-asserted-by":"crossref","unstructured":"Wiseman JA, Halliday GM, Dieriks BV. Neuronal \u03b1-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy. Brain. 2025.","DOI":"10.1093\/brain\/awaf030"},{"key":"900_CR24","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Disord. 2005;20:1255\u201363.","journal-title":"Mov disord"},{"key":"900_CR25","doi-asserted-by":"publisher","first-page":"1555175","DOI":"10.3389\/fneur.2025.1555175","volume":"16","author":"A Planas-Ballv\u00e9","year":"2025","unstructured":"Planas-Ballv\u00e9 A, Rios J, Ispierto L, Gea M, Grau L, Jim\u00e9nez M, C\u00e1ceres C, Mart\u00ednez S, Beyer K, \u00c1lvarez R, et al. Key motor and non-motor features in early dementia with Lewy bodies. Front Neurol. 2025;16:1555175.","journal-title":"Front Neurol"},{"key":"900_CR26","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1002\/alz.13357","volume":"19","author":"P Choudhury","year":"2023","unstructured":"Choudhury P, Zhang N, Adler CH, Chen K, Belden C, Driver-Dunckley E, Mehta SH, Shprecher DR, Serrano GE, Shill HA, et al. Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer\u2019s dementia in a community autopsy cohort. Alzheimers Dement. 2023;19:4377\u201387.","journal-title":"Alzheimers DeMent"},{"key":"900_CR27","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00415-013-6853-y","volume":"260","author":"M Onofrj","year":"2013","unstructured":"Onofrj M, Varanese S, Bonanni L, Taylor JP, Antonini A, Valente EM, Petrucci S, Stocchi F, Thomas A, Perfetti B. Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. J Neurol. 2013;260:1731\u201342.","journal-title":"J Neurol"},{"key":"900_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000333072","volume":"32","author":"E Auning","year":"2011","unstructured":"Auning E, Rongve A, Fladby T, Booij J, Hortob\u00e1gyi T, Siepel FJ, Ballard C, Aarsland D. Early and presenting symptoms of dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2011;32:202\u201308.","journal-title":"Dement Geriatr Cogn disord"},{"key":"900_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2012.09.007","volume":"323","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Vaid HM, Edun A, Dogu O, Rana MA. Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson\u2019s disease. J Neurol Sci. 2012;323:158\u201361.","journal-title":"J Neurol Sci"},{"key":"900_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/mds.25650","volume":"29","author":"CR Baumann","year":"2014","unstructured":"Baumann CR, Held U, Valko PO, Wienecke M, Waldvogel D. Body side and predominant motor features at the onset of Parkinson\u2019s disease are linked to motor and nonmotor progression. Mov Disord. 2014;29:207\u201313.","journal-title":"Mov disord"},{"key":"900_CR31","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1212\/WNL.0000000000002768","volume":"86","author":"van der Heeden Jf","year":"2016","unstructured":"van der Heeden Jf, Marinus J, Martinez-Martin P, Rodriguez-Blazquez C, Geraedts VJ, van Hilten Jj. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology. 2016;86:2243\u201350.","journal-title":"Neurology"},{"key":"900_CR32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/gps.5080","volume":"34","author":"AM Mayo","year":"2019","unstructured":"Mayo AM, Peavy GM. Associations among Braak stage, parkinsonian gait, cognition, and functional status in autopsy-confirmed dementia with Lewy bodies. Int J Geriatr Psychiatry. 2019;34:738\u201344.","journal-title":"Int J Geriatr Psychiatry"},{"key":"900_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mds.25213","volume":"28","author":"ML M\u00fcller","year":"2013","unstructured":"M\u00fcller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, Bohnen NI. \u03b2-amyloid and postural instability and gait difficulty in Parkinson\u2019s disease at risk for dementia. Mov Disord. 2013;28:296\u2013301.","journal-title":"Mov disord"},{"key":"900_CR34","doi-asserted-by":"publisher","first-page":"e 5521","DOI":"10.1371\/journal.pone.0005521","volume":"4","author":"LM Allan","year":"2009","unstructured":"Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One. 2009;4:e 5521.","journal-title":"PLoS One"},{"key":"900_CR35","doi-asserted-by":"crossref","unstructured":"Cheng KL, Lin LH, Chen PC, Chiang PL, Chen YS, Chen HL, Chen MH, Chou KH, Li SH, Lu CH, Lin WC. Reduced gray matter volume and risk of falls in Parkinson\u2019s disease with dementia patients: a voxel-based morphometry study. Int J Environ Res Public Health. 2020;17.","DOI":"10.3390\/ijerph17155374"},{"key":"900_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.26670","volume":"94","author":"T Nedelec","year":"2023","unstructured":"Nedelec T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, Monnet F, Gantzer L, Lekens B, Wu Y, Villain N, Schrag A, et al. A comparison between early presentation of dementia with Lewy Bodies, Alzheimer\u2019s disease, and Parkinson\u2019s disease: evidence from routine primary care and UK Biobank Data. Ann Neurol. 2023;94:259\u201370.","journal-title":"Ann Neurol"},{"key":"900_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jamaneurol.2014.4563","volume":"72","author":"MJ Howell","year":"2015","unstructured":"Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72:707\u201312.","journal-title":"JAMA Neurol"},{"key":"900_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/mds.27018","volume":"32","author":"EK St Louis","year":"2017","unstructured":"St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson\u2019s disease and other synucleinopathies. Mov Disord. 2017;32:645\u201358.","journal-title":"Mov disord"},{"key":"900_CR39","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Arcos A, Morenas-Rodr\u00edguez E, Santamaria J, S\u00e1nchez-Valle R, Llad\u00f3 A, Gaig C, Lle\u00f3 A, Iranzo A. Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. Sleep. 2019;42.","DOI":"10.1093\/sleep\/zsz086"},{"key":"900_CR40","doi-asserted-by":"publisher","first-page":"104996","DOI":"10.1016\/j.nbd.2020.104996","volume":"143","author":"MT Hu","year":"2020","unstructured":"Hu MT. REM sleep behavior disorder (RBD). Neurobiol Dis. 2020;143:104996.","journal-title":"Neurobiol Dis"},{"key":"900_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ana.25952","volume":"89","author":"CD Stang","year":"2021","unstructured":"Stang CD, Mullan AF, Hajeb M, Camerucci E, Turcano P, Martin P, Mielke MM, Josephs KA, Bower JH, St Louis EK, et al. Timeline of rapid eye movement Sleep behavior disorder in overt alpha-synucleinopathies. Ann Neurol. 2021;89:293\u2013303.","journal-title":"Ann Neurol"},{"key":"900_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/alz.12411","volume":"18","author":"P Choudhury","year":"2022","unstructured":"Choudhury P, Graff-Radford J, Aakre JA, Wurtz L, Knopman DS, Graff-Radford NR, Kantarci K, Forsberg LK, Fields JA, Pedraza O, et al. The temporal onset of the core features in dementia with Lewy bodies. Alzheimers Dement. 2022;18:591\u2013601.","journal-title":"Alzheimers DeMent"},{"key":"900_CR43","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1212\/WNL.0000000000006134","volume":"91","author":"G Pagano","year":"2018","unstructured":"Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91:e894\u2013905.","journal-title":"Neurology"},{"key":"900_CR44","doi-asserted-by":"crossref","unstructured":"Elder GJ, Lazar AS, Alfonso-Miller P, Taylor JP. Sleep disturbances in Lewy body dementia: a systematic review. Int J Geriatr Psychiatry. 2022;37.","DOI":"10.1002\/gps.5814"},{"key":"900_CR45","doi-asserted-by":"publisher","first-page":"e0243454","DOI":"10.1371\/journal.pone.0243454","volume":"15","author":"H Baumann-Vogel","year":"2020","unstructured":"Baumann-Vogel H, Hor H, Poryazova R, Valko P, Werth E, Baumann CR. REM sleep behavior in Parkinson disease: frequent, particularly with higher age. PLoS One. 2020;15:e0243454.","journal-title":"PLoS One"},{"key":"900_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.JGP.0000192480.89813.80","volume":"14","author":"UP Mosimann","year":"2006","unstructured":"Mosimann UP, Rowan EN, Partington CE, Collerton D, Littlewood E, O\u2019Brien JT, Burn DJ, McKeith IG. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14:153\u201360.","journal-title":"Am J Geriatr Psychiatry"},{"key":"900_CR47","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/mds.23891","volume":"26","author":"NK Archibald","year":"2011","unstructured":"Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Mov Disord. 2011;26:2387\u201395.","journal-title":"Mov disord"},{"key":"900_CR48","doi-asserted-by":"publisher","first-page":"e0205909","DOI":"10.1371\/journal.pone.0205909","volume":"13","author":"W Lin","year":"2018","unstructured":"Lin W, Xie YC, Cheng PY, Dong LY, Hung GU, Chiu PY. Association of visual hallucinations with very mild degenerative dementia due to dementia with Lewy bodies. PLoS One. 2018;13:e0205909.","journal-title":"PLoS One"},{"key":"900_CR49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528\u201336.","journal-title":"Int J Geriatr Psychiatry"},{"key":"900_CR50","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1001\/jamaneurol.2013.3579","volume":"70","author":"R Savica","year":"2013","unstructured":"Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70:1396\u2013402.","journal-title":"JAMA Neurol"},{"key":"900_CR51","doi-asserted-by":"publisher","first-page":"e0153989","DOI":"10.1371\/journal.pone.0153989","volume":"11","author":"PY Chiu","year":"2016","unstructured":"Chiu PY, Tsai CT, Chen PK, Chen WJ, Lai TJ. Neuropsychiatric symptoms in Parkinson\u2019s disease dementia are more similar to Alzheimer\u2019s disease than dementia with Lewy bodies: a case-control study. PLoS One. 2016;11:e0153989.","journal-title":"PLoS One"},{"key":"900_CR52","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1017\/S0033291718003161","volume":"49","author":"CL Eversfield","year":"2019","unstructured":"Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson\u2019s disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol Med. 2019;49:2342\u201353.","journal-title":"Psychol Med"},{"key":"900_CR53","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1212\/01.WNL.0000036908.39696.FD","volume":"59","author":"CG Ballard","year":"2002","unstructured":"Ballard CG, Aarsland D, McKeith I, O\u2019Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002;59:1714\u201320.","journal-title":"Neurology"},{"key":"900_CR54","doi-asserted-by":"crossref","unstructured":"Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2020 2087;94:e2076\u2013e.","DOI":"10.1212\/WNL.0000000000009434"},{"key":"900_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/JAD-210006","volume":"84","author":"G Palermo","year":"2021","unstructured":"Palermo G, Belli E, Tommasini L, Morganti R, Frosini D, Nicoletti V, Tognoni G, Siciliano G, Bonuccelli U, Baldacci F, Ceravolo R. Dissecting the interplay between time of dementia and cognitive profiles in Lewy Body Dementias. J Alzheimers Dis. 2021;84:757\u201366.","journal-title":"J Alzheimers Dis"},{"key":"900_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.2006.102343","volume":"78","author":"LM Allan","year":"2007","unstructured":"Allan LM, Ballard CG, Allen J, Murray A, Davidson AW, McKeith IG, Kenny RA. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry. 2007;78:671\u201377.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"900_CR57","doi-asserted-by":"publisher","first-page":"e45451","DOI":"10.1371\/journal.pone.0045451","volume":"7","author":"K Stubendorff","year":"2012","unstructured":"Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson\u2019s disease with dementia. PLoS One. 2012;7:e45451.","journal-title":"PLoS One"},{"key":"900_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00415-003-1029-9","volume":"250","author":"Y Horimoto","year":"2003","unstructured":"Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, Otsuka Y, Ojika K, Ueda R, Kosaka K. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol. 2003;250:530\u201333.","journal-title":"J Neurol"},{"key":"900_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/01.wnl.0000296826.61499.26","volume":"70","author":"GN Ransmayr","year":"2008","unstructured":"Ransmayr GN, Holliger S, Schletterer K, Heidler H, Deibl M, Poewe W, Madersbacher H, Kiss G. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70:299\u2013303.","journal-title":"Neurology"},{"key":"900_CR60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mds.25985","volume":"30","author":"F Tateno","year":"2015","unstructured":"Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, Sugiyama M, Tateno A. Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord. 2015;30:411\u201315.","journal-title":"Mov disord"},{"key":"900_CR61","doi-asserted-by":"publisher","first-page":"977572","DOI":"10.3389\/fnagi.2022.977572","volume":"14","author":"FF Li","year":"2022","unstructured":"Li FF, Cui YS, Yan R, Cao SS. Feng T. Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14:977572.","journal-title":"Front Aging neurosci"},{"key":"900_CR62","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s004010100390","volume":"102","author":"AJ Harding","year":"2001","unstructured":"Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102:355\u201363.","journal-title":"Acta Neuropathol"},{"issue":"Suppl, 1","key":"900_CR63","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.parkreldis.2004.10.014","volume":"11","author":"Y Tsuboi","year":"2005","unstructured":"Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson\u2019s disease with dementia: are they different? Parkinsonism Relat Disord. 2005;11(Suppl, 1):S47\u201351.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl, 3","key":"900_CR64","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1016\/S1353-8020(08)70005-1","volume":"13","author":"Y Tsuboi","year":"2007","unstructured":"Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson\u2019s disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord. 2007;13(Suppl, 3):S221\u2013224.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2009.05.083","volume":"461","author":"ME Kalaitzakis","year":"2009","unstructured":"Kalaitzakis ME, Pearce RK, Gentleman SM. Clinical correlates of pathology in the claustrum in Parkinson\u2019s disease and dementia with Lewy bodies. Neurosci Lett. 2009;461:12\u201315.","journal-title":"Neurosci Lett"},{"key":"900_CR66","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nbd.2010.10.005","volume":"41","author":"ME Kalaitzakis","year":"2011","unstructured":"Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal A\u03b2 peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol Dis. 2011;41:377\u201384.","journal-title":"Neurobiol Dis"},{"key":"900_CR67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/nan.12308","volume":"42","author":"M Sierra","year":"2016","unstructured":"Sierra M, Gelpi E, Mart\u00ed MJ. Compta Y. Lewy- and alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. Neuropathol Appl neurobiol. 2016;42:451\u201362.","journal-title":"Neuropathol Appl neurobiol"},{"key":"900_CR68","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00401-006-0088-2","volume":"112","author":"KA Jellinger","year":"2006","unstructured":"Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 2006;112:253\u201360.","journal-title":"Acta Neuropathol"},{"key":"900_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00702-011-0641-6","volume":"118","author":"GM Halliday","year":"2011","unstructured":"Halliday GM, Song YJ, Harding AJ. Striatal \u03b2-amyloid in dementia with Lewy bodies but not Parkinson\u2019s disease. J Neural Transm (Vienna). 2011;118:713\u201319.","journal-title":"J Neural Transm (vienna)"},{"key":"900_CR70","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/nan.12294","volume":"42","author":"C Ruffmann","year":"2016","unstructured":"Ruffmann C, Calboli FC, Bravi I, Gveric D, Curry LK, de Smith A, Pavlou S, Buxton JL, Blakemore AI, Takousis P, et al. Cortical Lewy bodies and A\u03b2 burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol. 2016;42:436\u201350.","journal-title":"Neuropathol Appl neurobiol"},{"key":"900_CR71","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp DH, Vergoossen DL, Huisman E, Lemstra AW, Berendse HW, Rozemuller AJ, Foncke EM, van de Berg WD. Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with Lewy Bodies. J Neuropathol Exp Neurol. 2016;75:936\u201345.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR72","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00702-021-02345-9","volume":"128","author":"KA Jellinger","year":"2021","unstructured":"Jellinger KA. Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. J Neural Transm (Vienna). 2021;128:687\u201399.","journal-title":"J Neural Transm (Vienna)"},{"key":"900_CR73","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00702-023-02660-3","volume":"130","author":"KA Jellinger","year":"2023","unstructured":"Jellinger KA. Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia. J Neural Transm (Vienna). 2023;130:891\u2013904.","journal-title":"J Neural Transm (Vienna)"},{"key":"900_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease? BMC Med. 2018;16:34.","journal-title":"BMC Med"},{"key":"900_CR75","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/mds.26721","volume":"31","author":"BF Boeve","year":"2016","unstructured":"Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, et al. Arguing against the proposed definition changes of PD. Mov Disord. 2016;31:1619\u201322.","journal-title":"Mov disord"},{"key":"900_CR76","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/ageing\/afi190","volume":"34","author":"J Zaccai","year":"2005","unstructured":"Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34:561\u201366.","journal-title":"Age Ageing"},{"key":"900_CR77","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44:673\u201383.","journal-title":"Psychol Med"},{"issue":"Suppl, 1","key":"900_CR78","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1017\/cjn.2016.2","volume":"43","author":"DB Hogan","year":"2016","unstructured":"Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, Steeves T, Smith EE, Pearson D, Jett\u00e9 N. The prevalence and incidence of dementia with Lewy Bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl, 1):S83\u201395.","journal-title":"Can J Neurol Sci"},{"key":"900_CR79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R, Fontana A, Liguori R, Logroscino G. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89:358\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"900_CR80","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s disease. The Lancet Neurol. 2021;20:385\u201397.","journal-title":"The Lancet Neurol"},{"key":"900_CR81","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archneur.57.8.1145","volume":"57","author":"V Haroutunian","year":"2000","unstructured":"Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, Mohs RC, Davis KL. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol. 2000;57:1145\u201350.","journal-title":"Arch Neurol"},{"key":"900_CR82","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/brain\/aws234","volume":"135","author":"JA Schneider","year":"2012","unstructured":"Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135:3005\u201314.","journal-title":"Brain"},{"key":"900_CR83","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/neup.12298","volume":"36","author":"H Honda","year":"2016","unstructured":"Honda H, Sasaki K, Hamasaki H, Shijo M, Koyama S, Ohara T, Ninomiya T, Kiyohara Y, Suzuki SO, Iwaki T. Trends in autopsy-verified dementia prevalence over 29 years of the hisayama study. Neuropathology. 2016;36:383\u201387.","journal-title":"Neuropathology"},{"key":"900_CR84","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8:S3\u2013s8.","journal-title":"J Parkinsons Dis"},{"key":"900_CR85","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/gps.5260","volume":"35","author":"H Sanghvi","year":"2020","unstructured":"Sanghvi H, Singh R, Morrin H, Rajkumar AP. Systematic review of genetic association studies in people with Lewy body dementia. Int J Geriatr Psychiatry. 2020;35:436\u201348.","journal-title":"Int J Geriatr Psychiatry"},{"key":"900_CR86","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","volume":"83","author":"N Zhao","year":"2018","unstructured":"Zhao N, Liu CC, Qiao W, Bu G. Apolipoprotein E, receptors, and modulation of Alzheimer\u2019s disease. Biol Psychiatry. 2018;83:347\u201357.","journal-title":"Biol Psychiatry"},{"key":"900_CR87","doi-asserted-by":"publisher","first-page":"1399965","DOI":"10.3389\/fnmol.2024.1399965","volume":"17","author":"HJ Moon","year":"2024","unstructured":"Moon HJ, Luo Y, Chugh D, Zhao L. Human apolipoprotein E glycosylation and sialylation: from structure to function. Front Mol Neurosci. 2024;17:1399965.","journal-title":"Front Mol neurosci"},{"key":"900_CR88","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1093\/hmg\/ddu334","volume":"23","author":"J Bras","year":"2014","unstructured":"Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014;23:6139\u201346.","journal-title":"Hum Mol Genet"},{"key":"900_CR89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","volume":"17","author":"R Guerreiro","year":"2018","unstructured":"Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, Shepherd CE, Parkkinen L, Darwent L, Heckman MG, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. The Lancet Neurol. 2018;17:64\u201374.","journal-title":"The Lancet Neurol"},{"key":"900_CR90","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1038\/s41598-019-43458-2","volume":"9","author":"A Rongve","year":"2019","unstructured":"Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hern\u00e1ndez I, Moreno-Grau S, de Rojas I, et al. GBA and APOE \u03b54 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep. 2019;9:7013.","journal-title":"Sci Rep"},{"key":"900_CR91","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","volume":"53","author":"R Chia","year":"2021","unstructured":"Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S, Viollet C, Ding J, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53:294\u2013303.","journal-title":"Nat Genet"},{"key":"900_CR92","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17:72.","journal-title":"Mol NeurodeGener"},{"key":"900_CR93","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-024-00988-2","volume":"20","author":"RJ Jackson","year":"2024","unstructured":"Jackson RJ, Hyman BT, Serrano-Pozo A. Multifaceted roles of APOE in Alzheimer disease. Nat Rev Neurol. 2024;20:457\u201374.","journal-title":"Nat Rev Neurol"},{"key":"900_CR94","doi-asserted-by":"crossref","unstructured":"Qu L, Xu S, Lan Z, Fang S, Xu Y, Zhu X. Apolipoprotein E in Alzheimer\u2019s disease: focus on synaptic function and therapeutic strategy. Mol Neurobiol. 2024.","DOI":"10.1007\/s12035-024-04449-1"},{"key":"900_CR95","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40478-024-01731-0","volume":"12","author":"AC Raulin","year":"2024","unstructured":"Raulin AC, Doss SV, Heckman MG, Craver EC, Li Z, Ikezu TC, Sekiya H, Liu CC, Martens YA, Rosenberg CL, et al. Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer\u2019s disease. Acta Neuropathol Commun. 2024;12:25.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR96","doi-asserted-by":"crossref","unstructured":"Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL, Diehl NN, van Gerpen JA, Uitti RJ, Wszolek ZK, Ertekin-Taner N, et al. APOE \u03b54 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018 1195;91:e1182\u2013e.","DOI":"10.1212\/WNL.0000000000006212"},{"key":"900_CR97","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, et al. APOE \u03b54 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70:223\u201328.","journal-title":"JAMA Neurol"},{"key":"900_CR98","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/brain\/awab402","volume":"145","author":"K Kaivola","year":"2022","unstructured":"Kaivola K, Shah Z, Chia R, Scholz SW. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain. 2022;145:1757\u201362.","journal-title":"Brain"},{"key":"900_CR99","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/brain\/awac414","volume":"146","author":"R Real","year":"2023","unstructured":"Real R, Martinez-Carrasco A, Reynolds RH, Lawton MA, Tan MMX, Shoai M, Corvol JC, Ryten M, Bresner C, Hubbard L, et al. Association between the LRP1B and APOE loci and the development of Parkinson\u2019s disease dementia. Brain. 2023;146:1873\u201387.","journal-title":"Brain"},{"key":"900_CR100","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mds.24946","volume":"27","author":"JF Morley","year":"2012","unstructured":"Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, et al. Genetic influences on cognitive decline in Parkinson\u2019s disease. Mov Disord. 2012;27:512\u201318.","journal-title":"Mov disord"},{"key":"900_CR101","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1038\/s41598-021-86483-w","volume":"11","author":"S Jo","year":"2021","unstructured":"Jo S, Kim SO, Park KW, Lee SH, Hwang YS, Chung SJ. The role of APOE in cognitive trajectories and motor decline in Parkinson\u2019s disease. Sci Rep. 2021;11:7819.","journal-title":"Sci Rep"},{"key":"900_CR102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neurobiolaging.2021.06.004","volume":"106","author":"JH Jung","year":"2021","unstructured":"Jung JH, Jeon S, Baik K, Lee YH, Chung SJ, Yoo HS, Jeong SH, Sohn YH, Lee PH, Ye BS. Apolipoprotein E4, amyloid, and cognition in Alzheimer\u2019s and Lewy body disease. Neurobiol Aging. 2021;106:45\u201354.","journal-title":"Neurobiol Aging"},{"key":"900_CR103","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3233\/JAD-220976","volume":"91","author":"JY Liu","year":"2023","unstructured":"Liu JY, Ma LZ, Wang J, Cui XJ, Sheng ZH, Fu Y, Li M, Ou YN, Yu JT, Tan L, Lian Y. Age-related association between APOE \u025b4 and cognitive progression in de novo Parkinson\u2019s disease. J Alzheimers Dis. 2023;91:1121\u201332.","journal-title":"J Alzheimers Dis"},{"key":"900_CR104","doi-asserted-by":"crossref","unstructured":"Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, Meneses AD, Li F, Shue F, Zheng J, et al. APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12.","DOI":"10.1126\/scitranslmed.aay1809"},{"key":"900_CR105","doi-asserted-by":"crossref","unstructured":"Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 2020;12.","DOI":"10.1126\/scitranslmed.aay3069"},{"key":"900_CR106","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-020-00226-x","volume":"10","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and \u03b1-synuclein in GBA-associated Parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review. Transl NeurodeGener. 2021;10:4.","journal-title":"Transl NeurodeGener"},{"key":"900_CR107","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1001\/archneurol.2009.54","volume":"66","author":"LN Clark","year":"2009","unstructured":"Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, Verbitsky M, Mejia-Santana H, Cote LJ, Andrews H, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol. 2009;66:578\u201383.","journal-title":"Arch Neurol"},{"key":"900_CR108","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","volume":"79","author":"D Tsuang","year":"2012","unstructured":"Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 2012;79:1944\u201350.","journal-title":"Neurology"},{"key":"900_CR109","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ajmg.b.32549","volume":"177","author":"B Creese","year":"2018","unstructured":"Creese B, Bell E, Johar I, Francis P, Ballard C, Aarsland D. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson\u2019s disease and Lewy body dementias: review and meta-analyses. Am J Med Genet B Neuropsychiatr Genet. 2018;177:232\u201341.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"900_CR110","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/brain\/awz350","volume":"143","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, Gibbs JR, Hernandez DG, Kumaran R, Langston R, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia. Brain. 2020;143:234\u201348.","journal-title":"Brain"},{"key":"900_CR111","doi-asserted-by":"publisher","first-page":"104856","DOI":"10.1016\/j.neubiorev.2022.104856","volume":"141","author":"S Gaubert","year":"2022","unstructured":"Gaubert S, Hourregue C, Mouton-Liger F, Millot P, Franco M, Amar-Bouaziz E, Aarsland D, Hugon J, Paquet C. Exploring the link between GBA1 mutations and dementia with Lewy bodies, a mini-review. Neurosci Biobehav Rev. 2022;141:104856.","journal-title":"Neurosci Biobehav Rev"},{"key":"900_CR112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL G\u00fcndner","year":"2019","unstructured":"G\u00fcndner AL, Duran-Pacheco G, Zimmermann S, Ruf I, Moors T, Baumann K, Jagasia R, van de Berg WDJ, Kremer T. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing \u03b1-synuclein levels. Neurobiol Dis. 2019;121:205\u201313.","journal-title":"Neurobiol Dis"},{"key":"900_CR113","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, Morris CM, Theuns J, Crosiers D, Cras P, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70:727\u201335.","journal-title":"JAMA Neurol"},{"key":"900_CR114","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","volume":"80","author":"G Liu","year":"2016","unstructured":"Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, et al. Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s. Ann Neurol. 2016;80:674\u201385.","journal-title":"Ann Neurol"},{"key":"900_CR115","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mds.26359","volume":"31","author":"IF Mata","year":"2016","unstructured":"Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, et al. GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson\u2019s disease. Mov Disord. 2016;31:95\u2013102.","journal-title":"Mov disord"},{"key":"900_CR116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. The Lancet Neurol. 2017;16:55\u201365.","journal-title":"The Lancet Neurol"},{"key":"900_CR117","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00401-024-02699-w","volume":"147","author":"RL Walton","year":"2024","unstructured":"Walton RL, Koga S, Beasley AI, White LJ, Griesacker T, Murray ME, Kasanuki K, Hou X, Fiesel FC, Springer W, et al. Role of GBA variants in Lewy body disease neuropathology. Acta Neuropathol. 2024;147:54.","journal-title":"Acta Neuropathol"},{"key":"900_CR118","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.410270309","volume":"27","author":"LI Golbe","year":"1990","unstructured":"Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson\u2019s disease. Ann Neurol. 1990;27:276\u201382.","journal-title":"Ann Neurol"},{"key":"900_CR119","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u201347.","journal-title":"Science"},{"key":"900_CR120","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kr\u00fcger","year":"1998","unstructured":"Kr\u00fcger R, Kuhn W, M\u00fcller T, Woitalla D, Graeber M, K\u00f6sel S, Przuntek H, Epplen JT, Sch\u00f6ls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u201308.","journal-title":"Nat Genet"},{"key":"900_CR121","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. Alpha-synuclein locus triplication causes Parkinson\u2019s disease. Science. 2003;302:841.","journal-title":"Science"},{"key":"900_CR122","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"MC Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. Lancet. 2004;364:1167\u201369.","journal-title":"Lancet"},{"key":"900_CR123","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","volume":"364","author":"P Ib\u00e1\u00f1ez","year":"2004","unstructured":"Ib\u00e1\u00f1ez P, Bonnet AM, D\u00e9barges B, Lohmann E, Tison F, Pollak P, Agid Y, D\u00fcrr A, Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson\u2019s disease. Lancet. 2004;364:1169\u201371.","journal-title":"Lancet"},{"key":"900_CR124","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atar\u00e9s B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164\u201373.","journal-title":"Ann Neurol"},{"key":"900_CR125","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/archneur.65.4.514","volume":"65","author":"T Ikeuchi","year":"2008","unstructured":"Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan CF, Idezuka J, Wakabayashi K, Onodera O, Iwatsubo T, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol. 2008;65:514\u201319.","journal-title":"Arch Neurol"},{"key":"900_CR126","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ana.21966","volume":"67","author":"K Seidel","year":"2010","unstructured":"Seidel K, Sch\u00f6ls L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, Dickson D, Gai WP, Bornemann A, Riess O, et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol. 2010;67:684\u201389.","journal-title":"Ann Neurol"},{"key":"900_CR127","first-page":"753","volume":"125","author":"AP Kiely","year":"2013","unstructured":"Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. \u03b1-Synucleinopathy associated with G51D SNCA Mutat: a link between Parkinson\u2019s Disease and Multiple System Atrophy? Acta Neuropathol. 2013;125:753\u201369.","journal-title":"\u03b1-Synucleinopathy Associated With G51D SNCA Mutat: A Link Between Parkinson\u2019s Disease And Multiple System Atrophy? Acta Neuropathol"},{"key":"900_CR128","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/mds.25421","volume":"28","author":"S Appel-Cresswell","year":"2013","unstructured":"Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease. Mov Disord. 2013;28:811\u201313.","journal-title":"Mov disord"},{"key":"900_CR129","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0b013e31828727ba","volume":"80","author":"C Proukakis","year":"2013","unstructured":"Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel \u03b1-synuclein missense mutation in Parkinson disease. Neurology. 2013;80:1062\u201364.","journal-title":"Neurology"},{"key":"900_CR130","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13024-015-0038-3","volume":"10","author":"AP Kiely","year":"2015","unstructured":"Kiely AP, Ling H, Asi YT, Kara E, Proukakis C, Schapira AH, Morris HR, Roberts HC, Lubbe S, Limousin P, et al. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodegener. 2015;10:41.","journal-title":"Mol NeurodeGener"},{"key":"900_CR131","doi-asserted-by":"publisher","first-page":"2180. e2181","DOI":"10.1016\/j.neurobiolaging.2014.03.024","volume":"35","author":"P Pasanen","year":"2014","unstructured":"Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, P\u00f6yh\u00f6nen M, Paetau A. Novel \u03b1-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson\u2019s disease-type pathology. Neurobiol Aging. 2014;35:2180. e2181\u201385.","journal-title":"Neurobiol Aging"},{"key":"900_CR132","doi-asserted-by":"publisher","first-page":"e248.247","DOI":"10.1016\/j.neurobiolaging.2017.05.022","volume":"57","author":"H Yoshino","year":"2017","unstructured":"Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson\u2019s disease. Neurobiol Aging. 2017;57:.e248.247\u2013248.212.","journal-title":"Neurobiol Aging"},{"key":"900_CR133","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/neup.12687","volume":"40","author":"A Kapasi","year":"2020","unstructured":"Kapasi A, Brosch JR, Nudelman KN, Agrawal S, Foroud TM, Schneider JA. A novel SNCA E83Q mutation in a case of dementia with Lewy bodies and atypical frontotemporal lobar degeneration. Neuropathology. 2020;40:620\u201326.","journal-title":"Neuropathology"},{"key":"900_CR134","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parkreldis.2021.06.023","volume":"89","author":"C Fevga","year":"2021","unstructured":"Fevga C, Park Y, Lohmann E, Kievit AJ, Breedveld GJ, Ferraro F, de Boer L, van Minkelen R, Hanagasi H, Boon A, et al. A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2021;89:63\u201372.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR135","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/mds.28534","volume":"36","author":"H Liu","year":"2021","unstructured":"Liu H, Koros C, Stroh\u00e4ker T, Schulte C, Bozi M, Varvaresos S, Ib\u00e1\u00f1ez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K, et al. A novel SNCA A30G mutation causes familial Parkinson\u2019s disease. Mov Disord. 2021;36:1624\u201333.","journal-title":"Mov disord"},{"key":"900_CR136","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/mds.29162","volume":"37","author":"K Daida","year":"2022","unstructured":"Daida K, Shimonaka S, Shiba-Fukushima K, Ogata J, Yoshino H, Okuzumi A, Hatano T, Motoi Y, Hirunagi T, Katsuno M, et al. \u03b1-synuclein V15A variant in familial Parkinson\u2019s disease exhibits a weaker lipid-binding property. Mov Disord. 2022;37:2075\u201385.","journal-title":"Mov disord"},{"key":"900_CR137","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-002-0563-3","volume":"104","author":"JE Duda","year":"2002","unstructured":"Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ. Concurrence of alpha-synuclein and tau brain pathology in the contursi kindred. Acta Neuropathol. 2002;104:7\u201311.","journal-title":"Acta Neuropathol"},{"key":"900_CR138","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ana.67","volume":"49","author":"PJ Spira","year":"2001","unstructured":"Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 2001;49:313\u201319.","journal-title":"Ann Neurol"},{"key":"900_CR139","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00401-005-1042-4","volume":"110","author":"K Yamaguchi","year":"2005","unstructured":"Yamaguchi K, Cochran EJ, Murrell JR, Polymeropoulos MH, Shannon KM, Crowther RA, Goedert M, Ghetti B. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol. 2005;110:298\u2013305.","journal-title":"Acta Neuropathol"},{"key":"900_CR140","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-008-0372-4","volume":"116","author":"K Markopoulou","year":"2008","unstructured":"Markopoulou K, Dickson DW, McComb RD, Wszolek ZK, Katechalidou L, Avery L, Stansbury MS, Chase BA. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson\u2019s disease. Variability in familial Parkinson\u2019s disease. Acta Neuropathol. 2008;116:25\u201335.","journal-title":"Acta Neuropathol"},{"key":"900_CR141","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.parkreldis.2020.11.001","volume":"81","author":"K Nishioka","year":"2020","unstructured":"Nishioka K, Hashizume Y, Takanashi M, Daida K, Li Y, Yoshino H, Tambasco N, Prontera P, Hattori Y, Ueda A, et al. Pathological findings in a patient with alpha-synuclein p.A53T and familial Parkinson\u2019s disease. Parkinsonism Relat Disord. 2020;81:183\u201387.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR142","doi-asserted-by":"publisher","first-page":"e1004741","DOI":"10.1371\/journal.pgen.1004741","volume":"10","author":"DF L\u00e1zaro","year":"2014","unstructured":"L\u00e1zaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, Gerhardt E, Kr\u00f6hnert K, Klucken J, Pereira MD, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014;10:e1004741.","journal-title":"PLoS Genet"},{"key":"900_CR143","doi-asserted-by":"publisher","first-page":"16696","DOI":"10.1038\/srep16696","volume":"5","author":"L Tosatto","year":"2015","unstructured":"Tosatto L, Horrocks MH, Dear AJ, Knowles TP, Dalla Serra M, Cremades N, Dobson CM, Klenerman D. Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson\u2019s disease genetically related mutants. Sci Rep. 2015;5:16696.","journal-title":"Sci Rep"},{"key":"900_CR144","doi-asserted-by":"publisher","first-page":"37630","DOI":"10.1038\/srep37630","volume":"6","author":"E Sierecki","year":"2016","unstructured":"Sierecki E, Giles N, Bowden Q, Polinkovsky ME, Steinbeck J, Arrioti N, Rahman D, Bhumkar A, Nicovich PR, Ross I, et al. Nanomolar oligomerization and selective co-aggregation of \u03b1-synuclein pathogenic mutants revealed by single-molecule fluorescence. Sci Rep. 2016;6:37630.","journal-title":"Sci Rep"},{"key":"900_CR145","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1021\/acschemneuro.8b00498","volume":"10","author":"VA Lima","year":"2019","unstructured":"Lima VA, Nascimento LA, Eliezer D, Follmer C. Role of Parkinson\u2019s disease-linked mutations and N-Terminal acetylation on the oligomerization of \u03b1-Synuclein induced by 3, 4-dihydroxyphenylacetaldehyde. ACS Chem Neurosci. 2019;10:690\u2013703.","journal-title":"ACS Chem Neurosci"},{"key":"900_CR146","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ana.24664","volume":"79","author":"I Guella","year":"2016","unstructured":"Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF, Goldman JG, Dalrymple-Alford JC, Geurtsen GJ, Litvan I, Ross OA, et al. \u03b1-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol. 2016;79:991\u201399.","journal-title":"Ann Neurol"},{"key":"900_CR147","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3389\/fneur.2018.01021","volume":"9","author":"A Book","year":"2018","unstructured":"Book A, Guella I, Candido T, Brice A, Hattori N, Jeon B, Farrer MJ. A meta-analysis of \u03b1-synuclein multiplication in familial parkinsonism. Front Neurol. 2018;9:1021.","journal-title":"Front Neurol"},{"key":"900_CR148","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00415-024-12836-w","volume":"272","author":"AM Simitsi","year":"2025","unstructured":"Simitsi AM, Sfikas E, Koros C, Papagiannakis N, Beratis I, Papadimitriou D, Antonellou R, Fragiadaki S, Kontaxopoulou D, Picillo M, et al. Motor and nonmotor features of p.A53T alpha-synuclein PD vs idiopathic PD: longitudinal data from the PPMI study. J Neurol. 2025;272:203.","journal-title":"J Neurol"},{"key":"900_CR149","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0896-6273(01)00462-7","volume":"32","author":"M Hashimoto","year":"2001","unstructured":"Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. Beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 2001;32:213\u201323.","journal-title":"Neuron"},{"key":"900_CR150","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/j.1742-4658.2007.05733.x","volume":"274","author":"IF Tsigelny","year":"2007","unstructured":"Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. The FEBS J. 2007;274:1862\u201377.","journal-title":"The FEBS J"},{"key":"900_CR151","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1093\/brain\/awq275","volume":"133","author":"K Beyer","year":"2010","unstructured":"Beyer K, Domingo-S\u00e0bat M, Santos C, Tolosa E, Ferrer I, Ariza A. The decrease of \u03b2-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain. 2010;133:3724\u201333.","journal-title":"Brain"},{"key":"900_CR152","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/JAD-180074","volume":"65","author":"A G\u00e1mez-Valero","year":"2018","unstructured":"G\u00e1mez-Valero A, Canet-Pons J, Urbizu A, Anillo A, Santos C, Ariza A, Beyer K. INDEL length and haplotypes in the \u03b2-Synuclein gene: a key to differentiate dementia with Lewy Bodies? J Alzheimers Dis. 2018;65:207\u201319.","journal-title":"J Alzheimers Dis"},{"key":"900_CR153","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ana.23905","volume":"74","author":"G Taschenberger","year":"2013","unstructured":"Taschenberger G, Toloe J, Tereshchenko J, Akerboom J, Wales P, Benz R, Becker S, Outeiro TF, Looger LL, B\u00e4hr M, et al. \u03b2-synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann Neurol. 2013;74:109\u201318.","journal-title":"Ann Neurol"},{"key":"900_CR154","doi-asserted-by":"crossref","unstructured":"Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray L IV VM, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology. 2004;63:805\u201311.","DOI":"10.1212\/01.WNL.0000139870.14385.3C"},{"key":"900_CR155","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/hmg\/ddab036","volume":"30","author":"M Psol","year":"2021","unstructured":"Psol M, Darvas SG, Leite K, Mahajani SU, B\u00e4hr M, K\u00fcgler S. Dementia with Lewy bodies-associated \u00df-synuclein mutations V70M and P123H cause mutation-specific neuropathological lesions. Hum Mol Genet. 2021;30:247\u201364.","journal-title":"Hum Mol Genet"},{"key":"900_CR156","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.neurobiolaging.2012.06.015","volume":"34","author":"M Colom-Cadena","year":"2013","unstructured":"Colom-Cadena M, Gelpi E, Mart\u00ed MJ, Charif S, Dols-Icardo O, Blesa R, Clarim\u00f3n J, Lle\u00f3 A. MAPT H1 haplotype is associated with enhanced \u03b1-synuclein deposition in dementia with Lewy bodies. Neurobiol Aging. 2013;34:936\u201342.","journal-title":"Neurobiol Aging"},{"key":"900_CR157","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jalz.2016.05.002","volume":"12","author":"C Labb\u00e9","year":"2016","unstructured":"Labb\u00e9 C, Heckman MG, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Murray ME, Allen M, Uitti RJ, Wszolek ZK, Smith GE, et al. MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimers Dement. 2016;12:1297\u2013304.","journal-title":"Alzheimers DeMent"},{"key":"900_CR158","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/mds.27773","volume":"34","author":"MG Heckman","year":"2019","unstructured":"Heckman MG, Kasanuki K, Brennan RR, Labb\u00e9 C, Vargas ER, Soto AI, Murray ME, Koga S, Dickson DW, Ross OA. Association of MAPT H1 subhaplotypes with neuropathology of Lewy body disease. Mov Disord. 2019;34:1325\u201332.","journal-title":"Mov disord"},{"key":"900_CR159","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/089198870201500406","volume":"15","author":"DW Dickson","year":"2002","unstructured":"Dickson DW. Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol. 2002;15:210\u201316.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"900_CR160","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. The Lancet Neurol. 2009;8:1150\u201357.","journal-title":"The Lancet Neurol"},{"key":"900_CR161","doi-asserted-by":"crossref","unstructured":"Dickson DW. Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2.","DOI":"10.1101\/cshperspect.a009258"},{"issue":"Suppl, 1","key":"900_CR162","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018;46(Suppl, 1):S30\u201333.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR163","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16:83.","journal-title":"Mol NeurodeGener"},{"key":"900_CR164","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00005072-196507000-00003","volume":"24","author":"PE Duffy","year":"1965","unstructured":"Duffy PE, Tennyson VM. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson\u2019s disease. J Neuropathol & Exp Neurol. 1965;24:398\u2013414.","journal-title":"J Neuropathol & Exp Neurol"},{"key":"900_CR165","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u201364.","journal-title":"Nat Cell Biol"},{"key":"900_CR166","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF00687787","volume":"75","author":"S Kuzuhara","year":"1988","unstructured":"Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. 1988;75:345\u201353.","journal-title":"Acta Neuropathol"},{"key":"900_CR167","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/00001756-200107200-00009","volume":"12","author":"E Kuusisto","year":"2001","unstructured":"Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport. 2001;12:2085\u201390.","journal-title":"Neuroreport"},{"key":"900_CR168","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnen\/62.12.1241","volume":"62","author":"E Kuusisto","year":"2003","unstructured":"Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol. 2003;62:1241\u201353.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR169","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1111\/j.1471-4159.1992.tb10074.x","volume":"58","author":"MS Pollanen","year":"1992","unstructured":"Pollanen MS, Bergeron C, Weyer L. Detergent-insoluble cortical Lewy body fibrils share epitopes with neurofilament and tau. J Neurochem. 1992;58:1953\u201356.","journal-title":"J NeuroChem"},{"key":"900_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00294352","volume":"88","author":"MS Pollanen","year":"1994","unstructured":"Pollanen MS, Bergeron C, Weyer L. Characterization of a shared epitope in cortical Lewy body fibrils and Alzheimer paired helical filaments. Acta Neuropathol. 1994;88:1\u20136.","journal-title":"Acta Neuropathol"},{"key":"900_CR171","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1750-3639.2007.00048.x","volume":"17","author":"JB Leverenz","year":"2007","unstructured":"Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 2007;17:139\u201345.","journal-title":"Brain Pathol"},{"key":"900_CR172","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.2741\/2973","volume":"13","author":"Q Xia","year":"2008","unstructured":"Xia Q, Liao L, Cheng D, Duong DM, Gearing M, Lah JJ, Levey AI, Peng J. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008;13:3850\u201356.","journal-title":"Front biosci"},{"issue":"Pt 5","key":"900_CR173","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283\u2013301.","journal-title":"Brain"},{"key":"900_CR174","doi-asserted-by":"crossref","unstructured":"Lewy F, Lewandowsky M. Handbuch der Neurologie. Berlin: Julius Springer. 1912.","DOI":"10.1097\/00005053-191206000-00015"},{"key":"900_CR175","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0304-3940(92)90923-U","volume":"138","author":"K Wakabayashi","year":"1992","unstructured":"Wakabayashi K, Takahashi H, Obata K, Ikuta F. Immunocytochemical localization of synaptic vesicle-specific protein in Lewy body-containing neurons in Parkinson\u2019s disease. Neurosci Lett. 1992;138:237\u201340.","journal-title":"Neurosci Lett"},{"key":"900_CR176","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00310030","volume":"83","author":"GE Dale","year":"1992","unstructured":"Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. Relationships between Lewy bodies and pale bodies in Parkinson\u2019s disease. Acta Neuropathol. 1992;83:525\u201329.","journal-title":"Acta Neuropathol"},{"key":"900_CR177","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00005072-196104000-00007","volume":"20","author":"H Okazaki","year":"1961","unstructured":"Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol. 1961;20:237\u201344.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR178","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1212\/WNL.41.9.1402","volume":"41","author":"DW Dickson","year":"1991","unstructured":"Dickson DW, Ruan D, Crystal H, Mark MH, Davies P, Kress Y, Yen SH. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer\u2019s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology. 1991;41:1402\u201309.","journal-title":"Neurology"},{"key":"900_CR179","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863\u201372.","journal-title":"Neurology"},{"key":"900_CR180","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1750-3639.2008.00140.x","volume":"18","author":"T Kanazawa","year":"2008","unstructured":"Kanazawa T, Uchihara T, Takahashi A, Nakamura A, Orimo S, Mizusawa H. Three-layered structure shared between Lewy bodies and Lewy neurites-three-dimensional reconstruction of triple-labeled sections. Brain Pathol. 2008;18:415\u201322.","journal-title":"Brain Pathol"},{"key":"900_CR181","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"900_CR182","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689\u2013702.","journal-title":"Acta Neuropathol"},{"key":"900_CR183","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-020-02233-8","volume":"141","author":"ZI Tanei","year":"2021","unstructured":"Tanei ZI, Saito Y, Ito S, Matsubara T, Motoda A, Yamazaki M, Sakashita Y, Kawakami I, Ikemura M, Tanaka S, et al. Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. Acta Neuropathol. 2021;141:25\u201337.","journal-title":"Acta Neuropathol"},{"key":"900_CR184","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1212\/WNL.0000000000200110","volume":"98","author":"T Matsubara","year":"2022","unstructured":"Matsubara T, Kameyama M, Tanaka N, Sengoku R, Orita M, Furuta K, Iwata A, Arai T, Maruyama H, Saito Y, Murayama S. Autopsy validation of the diagnostic accuracy of (123)I-Metaiodobenzylguanidine myocardial scintigraphy for Lewy Body Disease. Neurology. 2022;98:e1648\u2013e 1659.","journal-title":"Neurology"},{"key":"900_CR185","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/BF00688209","volume":"78","author":"LA Hansen","year":"1989","unstructured":"Hansen LA, Masliah E, Terry RD, Mirra SS. A neuropathological subset of Alzheimer\u2019s disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol. 1989;78:194\u2013201.","journal-title":"Acta Neuropathol"},{"key":"900_CR186","first-page":"369","volume":"1","author":"Y Fujino","year":"2008","unstructured":"Fujino Y, Dickson DW. Limbic lobe microvacuolation is minimal in Alzheimer\u2019s disease in the absence of concurrent Lewy body disease. Int J Clin Exp Pathol. 2008;1:369\u201375.","journal-title":"Int J Clin Exp Pathol"},{"key":"900_CR187","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0022-510X(97)05387-2","volume":"149","author":"E Iseki","year":"1997","unstructured":"Iseki E, Li F, Odawara T, Kosaka K. Hippocampal pathology in diffuse Lewy body disease using ubiquitin immunohistochemistry. J Neurol Sci. 1997;149:165\u201369.","journal-title":"J Neurol Sci"},{"key":"900_CR188","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/WAD.0b013e318256d507","volume":"27","author":"A Sherzai","year":"2013","unstructured":"Sherzai A, Edland SD, Masliah E, Hansen L, Pizzo DP, Sherzai A, Corey-Bloom J. Spongiform change in dementia with Lewy bodies and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:157\u201361.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"900_CR189","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1750-3639.1995.tb00625.x","volume":"5","author":"H Budka","year":"1995","unstructured":"Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Jellinger K, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol. 1995;5:459\u201366.","journal-title":"Brain Pathol"},{"key":"900_CR190","first-page":"185","volume":"3","author":"K Kosaka","year":"1984","unstructured":"Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease? Clin neuropathol. 1984;3:185\u201392.","journal-title":"Clin neuropathol"},{"key":"900_CR191","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117:613\u201334.","journal-title":"Acta Neuropathol"},{"key":"900_CR192","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/jnen\/62.6.644","volume":"62","author":"Y Saito","year":"2003","unstructured":"Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol. 2003;62:644\u201354.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR193","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/01.jnen.0000225908.90052.07","volume":"65","author":"H Uchikado","year":"2006","unstructured":"Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65:685\u201397.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR194","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0304-3940(99)00178-0","volume":"265","author":"E Iseki","year":"1999","unstructured":"Iseki E, Marui W, Kosaka K, U\u00e9da K. Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett. 1999;265:9\u201312.","journal-title":"Neurosci Lett"},{"key":"900_CR195","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","volume":"62","author":"T Ishizawa","year":"2003","unstructured":"Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003;62:389\u201397.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR196","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00401-008-0383-1","volume":"116","author":"H Fujishiro","year":"2008","unstructured":"Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer\u2019s disease with amygdala Lewy bodies. Acta Neuropathol. 2008;116:17\u201324.","journal-title":"Acta Neuropathol"},{"key":"900_CR197","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1750-3639.2007.00117.x","volume":"18","author":"JB Leverenz","year":"2008","unstructured":"Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008;18:220\u201324.","journal-title":"Brain Pathol"},{"key":"900_CR198","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00401-009-0523-2","volume":"117","author":"I Alafuzoff","year":"2009","unstructured":"Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, et al. Staging\/Typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe consortium. Acta Neuropathol. 2009;117:635\u201352.","journal-title":"Acta Neuropathol"},{"key":"900_CR199","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G, Hortobagyi T, Jellinger K, Kovacs GG, Lee EB, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141:159\u201372.","journal-title":"Acta Neuropathol"},{"key":"900_CR200","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136:2419\u201331.","journal-title":"Brain"},{"key":"900_CR201","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00401-008-0345-7","volume":"115","author":"DW Dickson","year":"2008","unstructured":"Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson\u2019s disease. Acta Neuropathol. 2008;115:437\u201344.","journal-title":"Acta Neuropathol"},{"key":"900_CR202","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-023-00622-7","volume":"18","author":"T Koeglsperger","year":"2023","unstructured":"Koeglsperger T, Rumpf SL, Schlie\u00dfer P, Struebing FL, Brendel M, Levin J, Trenkwalder C, H\u00f6glinger GU, Herms J. Neuropathology of incidental Lewy body & prodromal Parkinson\u2019s disease. Mol NeurodeGener. 2023;18:32.","journal-title":"Mol NeurodeGener"},{"key":"900_CR203","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/mds.25776","volume":"29","author":"E Gelpi","year":"2014","unstructured":"Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, Mart\u00ed MJ, Hern\u00e1ndez I, Valldeoriola F, Re\u00f1\u00e9 R, Ribalta T. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014;29:1010\u201318.","journal-title":"Mov disord"},{"key":"900_CR204","first-page":"1714","volume":"7","author":"S Ito","year":"2014","unstructured":"Ito S, Takao M, Hatsuta H, Kanemaru K, Arai T, Saito Y, Fukayama M, Murayama S. Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease. Int J Clin Exp Pathol. 2014;7:1714\u201323.","journal-title":"Int J Clin Exp Pathol"},{"key":"900_CR205","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jnen\/nlac023","volume":"81","author":"J Jotanovic","year":"2022","unstructured":"Jotanovic J, Milin-Lazovic J, Alafuzoff I. Gastrointestinal biopsy obtained during cancer screening, a biological Marker for \u03b1-synucleinopathy? J Neuropathol Exp Neurol. 2022;81:356\u201362.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR206","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JPD-150680","volume":"6","author":"TG Beach","year":"2016","unstructured":"Beach TG, Adler CH, Serrano G, Sue LI, Walker DG, Dugger BN, Shill HA, Driver-Dunckley E, Caviness JN, Intorcia A, et al. Prevalence of submandibular gland synucleinopathy in Parkinson\u2019s disease, dementia with Lewy bodies and other Lewy body disorders. J Parkinsons Dis. 2016;6:153\u201363.","journal-title":"J Parkinsons Dis"},{"key":"900_CR207","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/neup.12772","volume":"41","author":"Y Sakashita","year":"2021","unstructured":"Sakashita Y, Matsubara T, Takata T, Tanei ZI, Motoda A, Yamazaki M, Kawakami I, Sengoku R, Saito Y, Arai T, et al. Lewy pathology of the submandibular gland in Lewy body disease: a report of autopsy cases. Neuropathology. 2021;41:476\u201383.","journal-title":"Neuropathology"},{"key":"900_CR208","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/NEN.0b013e318186de48","volume":"67","author":"M Ikemura","year":"2008","unstructured":"Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol. 2008;67:945\u201353.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR209","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","volume":"89","author":"V Donadio","year":"2017","unstructured":"Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M, Devigili G, Eleopra R, Defazio G, Montini F, et al. A new potential biomarker for dementia with Lewy bodies: skin nerve \u03b1-synuclein deposits. Neurology. 2017;89:318\u201326.","journal-title":"Neurology"},{"key":"900_CR210","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, Agarwal P, Aldridge GM, Barboi A, Evidente VGH, et al. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA. 2024;331:1298\u2013306.","journal-title":"JAMA"},{"key":"900_CR211","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1212\/WNL.52.6.1269","volume":"52","author":"K Iwanaga","year":"1999","unstructured":"Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H. Lewy body-type degeneration in cardiac plexus in Parkinson\u2019s and incidental Lewy body diseases. Neurology. 1999;52:1269\u201371.","journal-title":"Neurology"},{"key":"900_CR212","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/brain\/awm302","volume":"131","author":"S Orimo","year":"2008","unstructured":"Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease. Brain. 2008;131:642\u201350.","journal-title":"Brain"},{"key":"900_CR213","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/nen.0b013e3180517454","volume":"66","author":"Y Fumimura","year":"2007","unstructured":"Fumimura Y, Ikemura M, Saito Y, Sengoku R, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol. 2007;66:354\u201362.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR214","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-022-01487-5","volume":"10","author":"A Raunio","year":"2022","unstructured":"Raunio A, Kivist\u00f6 V, Kero M, Tuimala J, Savola S, Oinas M, Kok E, Colangelo K, Paetau A, Polvikoski T, et al. Distribution of Lewy-related pathology in the brain, spinal cord, and periphery: the population-based Vantaa 85 + study. Acta Neuropathol Commun. 2022;10:178.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR215","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41593-024-01866-2","volume":"28","author":"X Yuan","year":"2025","unstructured":"Yuan X, Nie S, Yang Y, Liu C, Xia D, Meng L, Xia Y, Su H, Zhang C, Bu L, et al. Propagation of pathologic \u03b1-synuclein from kidney to brain may contribute to Parkinson\u2019s disease. Nat Neurosci. 2025;28:577\u201388.","journal-title":"Nat neurosci"},{"key":"900_CR216","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00401-024-02769-z","volume":"148","author":"H de Ruyter Fj","year":"2024","unstructured":"de Ruyter Fj H, Evers M, Morrema THJ, Dijkstra AA, den Haan J, Twisk JWR, de Boer Jf, Scheltens P, Bouwman FH, Verbraak FD, et al. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases. Acta Neuropathol. 2024;148:24.","journal-title":"Acta Neuropathol"},{"key":"900_CR217","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","volume":"22","author":"DE Cabin","year":"2002","unstructured":"Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002;22:8797\u2013807.","journal-title":"J. neurosci"},{"key":"900_CR218","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.brainres.2011.01.064","volume":"1382","author":"H Chadchankar","year":"2011","unstructured":"Chadchankar H, Ihalainen J, Tanila H, Yavich L. Decreased reuptake of dopamine in the dorsal striatum in the absence of \u03b1-synuclein. Brain Res. 2011;1382:37\u201344.","journal-title":"Brain Res"},{"key":"900_CR219","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","volume":"65","author":"VM Nemani","year":"2010","unstructured":"Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66\u201379.","journal-title":"Neuron"},{"key":"900_CR220","doi-asserted-by":"publisher","first-page":"8083","DOI":"10.1523\/JNEUROSCI.1091-10.2010","volume":"30","author":"DA Scott","year":"2010","unstructured":"Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083\u201395.","journal-title":"J. neurosci"},{"key":"900_CR221","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/brain\/awq132","volume":"133","author":"P Garcia-Reitb\u00f6ck","year":"2010","unstructured":"Garcia-Reitb\u00f6ck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P, Tofaris GK, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson\u2019s disease. Brain. 2010;133:2032\u201344.","journal-title":"Brain"},{"key":"900_CR222","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s10571-023-01355-3","volume":"43","author":"E Brolin","year":"2023","unstructured":"Brolin E, Ingelsson M, Bergstr\u00f6m J, Erlandsson A. Altered distribution of SNARE proteins in primary neurons exposed to different alpha-synuclein proteoforms. Cell Mol Neurobiol. 2023;43:3023\u201335.","journal-title":"Cell Mol Neurobiol"},{"key":"900_CR223","doi-asserted-by":"publisher","first-page":"639414","DOI":"10.3389\/fnins.2021.639414","volume":"15","author":"C Rom\u00e1n-Vendrell","year":"2021","unstructured":"Rom\u00e1n-Vendrell C, Medeiros AT, Sanderson JB, Jiang H, Bartels T, Morgan JR. Effects of excess brain-derived human \u03b1-synuclein on synaptic vesicle trafficking. Front Neurosci. 2021;15:639414.","journal-title":"Front neurosci"},{"key":"900_CR224","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00401-020-02177-z","volume":"141","author":"S Fanning","year":"2021","unstructured":"Fanning S, Selkoe D, Dettmer U. Vesicle trafficking and lipid metabolism in synucleinopathy. Acta Neuropathol. 2021;141:491\u2013510.","journal-title":"Acta Neuropathol"},{"key":"900_CR225","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1038\/s41598-017-06724-9","volume":"7","author":"JA Phan","year":"2017","unstructured":"Phan JA, Stokholm K, Zareba-Paslawska J, Jakobsen S, Vang K, Gjedde A, Landau AM, Romero-Ramos M. Early synaptic dysfunction induced by \u03b1-synuclein in a rat model of Parkinson\u2019s disease. Sci Rep. 2017;7:6363.","journal-title":"Sci Rep"},{"key":"900_CR226","doi-asserted-by":"crossref","unstructured":"Longhena F, Faustini G, Missale C, Pizzi M, Bellucci A. Dopamine transporter\/\u03b1-synuclein complexes are altered in the post mortem caudate putamen of Parkinson\u2019s disease: an in situ proximity ligation assay study. Int J Mol Sci. 2018;19.","DOI":"10.3390\/ijms19061611"},{"key":"900_CR227","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awab242","volume":"144","author":"A Tozzi","year":"2021","unstructured":"Tozzi A, Sciaccaluga M, Loffredo V, Megaro A, Ledonne A, Cardinale A, Federici M, Bellingacci L, Paciotti S, Ferrari E, et al. Dopamine-dependent early synaptic and motor dysfunctions induced by \u03b1-synuclein in the nigrostriatal circuit. Brain. 2021;144:3477\u201391.","journal-title":"Brain"},{"key":"900_CR228","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/brain\/aws133","volume":"135","author":"Y Chu","year":"2012","unstructured":"Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, Kordower JH. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson\u2019s disease. Brain. 2012;135:2058\u201373.","journal-title":"Brain"},{"key":"900_CR229","doi-asserted-by":"publisher","first-page":"e 1811","DOI":"10.1038\/cddis.2015.169","volume":"6","author":"JC Koch","year":"2015","unstructured":"Koch JC, Bitow F, Haack J, d\u2019Hedouville Z, Zhang JN, T\u00f6nges L, Michel U, Oliveira LM, Jovin TM, Liman J, et al. Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis. 2015;6:e 1811.","journal-title":"Cell Death Dis"},{"key":"900_CR230","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.1520335113","volume":"113","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. \u03b1-synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci USA. 2016;113:1931\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR231","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41419-021-04138-0","volume":"12","author":"Q Tang","year":"2021","unstructured":"Tang Q, Gao P, Arzberger T, H\u00f6llerhage M, Herms J, H\u00f6glinger G, Koeglsperger T. Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. Cell Death Dis. 2021;12:854.","journal-title":"Cell Death Dis"},{"key":"900_CR232","doi-asserted-by":"publisher","first-page":"20288","DOI":"10.1074\/jbc.M710560200","volume":"283","author":"NY Zhang","year":"2008","unstructured":"Zhang NY, Tang Z, Liu CW. Alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J Biol Chem. 2008;283:20288\u201398.","journal-title":"J Biol Chem"},{"key":"900_CR233","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40478-020-0894-0","volume":"8","author":"C McKinnon","year":"2020","unstructured":"McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O\u2019Hara DM, Brotchie JM, Koprich JB, Lozano AM, et al. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by \u03b1-synuclein. Acta Neuropathol Commun. 2020;8:17.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR234","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40478-019-0696-4","volume":"7","author":"X Wang","year":"2019","unstructured":"Wang X, Becker K, Levine N, Zhang M, Lieberman AP, Moore DJ, Ma J. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathol Commun. 2019;7:41.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR235","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41419-023-06251-8","volume":"14","author":"O Lurette","year":"2023","unstructured":"Lurette O, Mart\u00edn-Jim\u00e9nez R, Khan M, Sheta R, Jean S, Schofield M, Teixeira M, Rodriguez-Aller R, Perron I, Oueslati A, Hebert-Chatelain E. Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization. Cell Death Dis. 2023;14:729.","journal-title":"Cell Death Dis"},{"key":"900_CR236","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13024-024-00756-2","volume":"19","author":"FF Geibl","year":"2024","unstructured":"Geibl FF, Henrich MT, Xie Z, Zampese E, Ueda J, Tkatch T, Wokosin DL, Nasiri E, Grotmann CA, Dawson VL, et al. \u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson\u2019s disease. Mol NeurodeGener. 2024;19:69.","journal-title":"Mol NeurodeGener"},{"key":"900_CR237","doi-asserted-by":"publisher","first-page":"e62143","DOI":"10.1371\/journal.pone.0062143","volume":"8","author":"D Freeman","year":"2013","unstructured":"Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O\u2019Connor C, et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One. 2013;8:e62143.","journal-title":"PLoS One"},{"key":"900_CR238","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00018-024-05419-5","volume":"81","author":"L Dai","year":"2024","unstructured":"Dai L, Liu M, Ke W, Chen L, Fang X, Zhang Z. Lysosomal dysfunction in \u03b1-synuclein pathology: Molecular mechanisms and therapeutic strategies. Cell Mol Life Sci. 2024;81:382.","journal-title":"Cell. Mol. Life Sci"},{"key":"900_CR239","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","volume":"117","author":"AL Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, Leleu M, Knott GW, Lashuel HA. The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci USA. 2020;117:4971\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR240","doi-asserted-by":"publisher","first-page":"e1009359","DOI":"10.1371\/journal.pgen.1009359","volume":"17","author":"S Sarkar","year":"2021","unstructured":"Sarkar S, Olsen AL, Sygnecka K, Lohr KM. Feany MB. \u03b1-synuclein impairs autophagosome maturation through abnormal actin stabilization. PLoS Genet. 2021;17:e1009359.","journal-title":"PLoS Genet"},{"key":"900_CR241","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1111\/febs.15674","volume":"288","author":"YR Choi","year":"2021","unstructured":"Choi YR, Park SJ, Park SM. Molecular events underlying the cell-to-cell transmission of \u03b1-synuclein. The FEBS J. 2021;288:6593\u2013602.","journal-title":"The FEBS J"},{"key":"900_CR242","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","volume":"79","author":"GK Tofaris","year":"2022","unstructured":"Tofaris GK. Initiation and progression of \u03b1-synuclein pathology in Parkinson\u2019s disease. Cell Mol Life Sci. 2022;79:210.","journal-title":"Cell. Mol. Life Sci"},{"key":"900_CR243","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","volume":"37","author":"R Sharon","year":"2003","unstructured":"Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease. Neuron. 2003;37:583\u201395.","journal-title":"Neuron"},{"key":"900_CR244","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00018-022-04166-9","volume":"79","author":"R Cascella","year":"2022","unstructured":"Cascella R, Bigi A, Cremades N, Cecchi C. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cell Mol Life Sci. 2022;79:174.","journal-title":"Cell. Mol. Life Sci"},{"key":"900_CR245","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1474-4422(04)00827-0","volume":"3","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. The Lancet Neurol. 2004;3:496\u2013503.","journal-title":"The Lancet Neurol"},{"key":"900_CR246","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders. Mol Neurobiol. 2013;47:495\u2013508.","journal-title":"Mol neurobiol"},{"key":"900_CR247","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00441-018-2854-6","volume":"373","author":"S Chartier","year":"2018","unstructured":"Chartier S, Duyckaerts C. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity? Cell Tissue Res. 2018;373:149\u201360.","journal-title":"Cell Tissue Res"},{"key":"900_CR248","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nn1443","volume":"8","author":"L Chen","year":"2005","unstructured":"Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657\u201363.","journal-title":"Nat neurosci"},{"key":"900_CR249","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.neuroscience.2011.10.018","volume":"199","author":"Z Sultana","year":"2011","unstructured":"Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM. Dynamic modeling of \u03b1-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson\u2019s therapy. Neuroscience. 2011;199:303\u201317.","journal-title":"Neuroscience"},{"key":"900_CR250","doi-asserted-by":"publisher","first-page":"e70027","DOI":"10.1002\/cnm.70027","volume":"41","author":"AV Kuznetsov","year":"2025","unstructured":"Kuznetsov AV. Criterion for assessing accumulated neurotoxicity of alpha-synuclein oligomers in Parkinson\u2019s disease. Int J Numer Method Biomed Eng. 2025;41:e70027.","journal-title":"Int J Numer Method Biomed Eng"},{"key":"900_CR251","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jalz.2017.09.014","volume":"14","author":"TJ Ferman","year":"2018","unstructured":"Ferman TJ, Aoki N, Crook JE, Murray ME, Graff-Radford NR, van Gerpen JA, Uitti RJ, Wszolek ZK, Graff-Radford J, Pedraza O, et al. The limbic and neocortical contribution of \u03b1-synuclein, tau, and amyloid \u03b2 to disease duration in dementia with Lewy bodies. Alzheimers DeMent. 2018;14:330\u201339.","journal-title":"Alzheimers DeMent"},{"key":"900_CR252","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2016.4926","volume":"74","author":"J Graff-Radford","year":"2017","unstructured":"Graff-Radford J, Aakre J, Savica R, Boeve B, Kremers WK, Ferman TJ, Jones DT, Kantarci K, Knopman DS, Dickson DW, et al. Duration and pathologic correlates of Lewy body disease. JAMA Neurol. 2017;74:310\u201315.","journal-title":"JAMA Neurol"},{"key":"900_CR253","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jnen\/nlz080","volume":"78","author":"CH Adler","year":"2019","unstructured":"Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Sabbagh MN, Serrano GE, Sue LI, et al. Unified staging system for Lewy body disorders: clinicopathologic correlations and comparison to Braak staging. J Neuropathol Exp Neurol. 2019;78:891\u201399.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR254","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","volume":"54","author":"HI Hurtig","year":"2000","unstructured":"Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson\u2019s disease. Neurology. 2000;54:1916\u201321.","journal-title":"Neurology"},{"key":"900_CR255","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archneur.59.1.102","volume":"59","author":"H Apaydin","year":"2002","unstructured":"Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59:102\u201312.","journal-title":"Arch Neurol"},{"key":"900_CR256","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/brain\/awq059","volume":"133","author":"PA Kempster","year":"2010","unstructured":"Kempster PA, O\u2019Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson\u2019s disease: a clinico-pathological study. Brain. 2010;133:1755\u201362.","journal-title":"Brain"},{"key":"900_CR257","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72:587\u201398.","journal-title":"Ann Neurol"},{"key":"900_CR258","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.parkreldis.2013.05.010","volume":"19","author":"J Horvath","year":"2013","unstructured":"Horvath J, Herrmann FR, Burkhard PR, Bouras C, K\u00f6vari E. Neuropathology of dementia in a large cohort of patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19:864\u201368; discussion 864.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR259","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","volume":"67","author":"JE Galvin","year":"2006","unstructured":"Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605\u201311.","journal-title":"Neurology"},{"key":"900_CR260","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.parkreldis.2009.02.003","volume":"15","author":"LS Libow","year":"2009","unstructured":"Libow LS, Frisina PG, Haroutunian V, Perl DP, Purohit DP. Parkinson\u2019s disease dementia: a diminished role for the Lewy body. Parkinsonism Relat Disord. 2009;15:572\u201375.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR261","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/jnnp.74.7.852","volume":"74","author":"C Colosimo","year":"2003","unstructured":"Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2003;74:852\u201356.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"900_CR262","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ana.20321","volume":"57","author":"L Parkkinen","year":"2005","unstructured":"Parkkinen L, Kauppinen T, Pirttil\u00e4 T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol. 2005;57:82\u201391.","journal-title":"Ann Neurol"},{"key":"900_CR263","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2008.03.015","volume":"31","author":"S Greffard","year":"2010","unstructured":"Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ. Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging. 2010;31:99\u2013103.","journal-title":"Neurobiol Aging"},{"key":"900_CR264","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004010050843","volume":"95","author":"PM Mattila","year":"1998","unstructured":"Mattila PM, R\u00f6ytt\u00e4 M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and alzheimer-type changes in patients with Parkinson\u2019s disease. Acta Neuropathol. 1998;95:576\u201382.","journal-title":"Acta Neuropathol"},{"key":"900_CR265","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","volume":"100","author":"PM Mattila","year":"2000","unstructured":"Mattila PM, Rinne JO, Helenius H, Dickson DW, R\u00f6ytt\u00e4 M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease. Acta Neuropathol. 2000;100:285\u201390.","journal-title":"Acta Neuropathol"},{"key":"900_CR266","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1212\/01.WNL.0000158422.41380.82","volume":"64","author":"H Braak","year":"2005","unstructured":"Braak H, R\u00fcb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64:1404\u201310.","journal-title":"Neurology"},{"key":"900_CR267","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bpa.12182","volume":"25","author":"DR Howlett","year":"2015","unstructured":"Howlett DR, Whitfield D, Johnson M, Attems J, O\u2019Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol. 2015;25:401\u201308.","journal-title":"Brain Pathol"},{"key":"900_CR268","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ana.20635","volume":"58","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson\u2019s disease: a prospective, community-based study. Ann Neurol. 2005;58:773\u201376.","journal-title":"Ann Neurol"},{"key":"900_CR269","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","volume":"60","author":"AR Merdes","year":"2003","unstructured":"Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60:1586\u201390.","journal-title":"Neurology"},{"key":"900_CR270","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1176\/appi.ajp.161.5.843","volume":"161","author":"CG Ballard","year":"2004","unstructured":"Ballard CG, Jacoby R, Del Ser T, Khan MN, Munoz DG, Holmes C, Nagy Z, Perry EK, Joachim C, Jaros E, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry. 2004;161:843\u201349.","journal-title":"Am J Psychiatry"},{"key":"900_CR271","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JGP.0b013e3181953b9a","volume":"17","author":"D Tsuang","year":"2009","unstructured":"Tsuang D, Larson EB, Bolen E, Thompson ML, Peskind E, Bowen J, McCormick W, Teri L, Kukull W, Vavrek D, et al. Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry. 2009;17:317\u201323.","journal-title":"Am J Geriatr Psychiatry"},{"key":"900_CR272","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.parkreldis.2012.10.013","volume":"19","author":"TJ Ferman","year":"2013","unstructured":"Ferman TJ, Arvanitakis Z, Fujishiro H, Duara R, Parfitt F, Purdy M, Waters C, Barker W, Graff-Radford NR, Dickson DW. Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer\u2019s disease. Parkinsonism Relat Disord. 2013;19:227\u201331.","journal-title":"Parkinsonism Relat Disord"},{"key":"900_CR273","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391\u2013403.","journal-title":"Brain"},{"key":"900_CR274","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jns.2006.02.016","volume":"246","author":"R Yamamoto","year":"2006","unstructured":"Yamamoto R, Iseki E, Murayama N, Minegishi M, Marui W, Togo T, Katsuse O, Kato M, Iwatsubo T, Kosaka K, Arai H. Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies. J Neurol Sci. 2006;246:95\u2013101.","journal-title":"J Neurol Sci"},{"key":"900_CR275","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1212\/WNL.62.2.181","volume":"62","author":"TJ Ferman","year":"2004","unstructured":"Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, Graff-Radford N, Parisi J, Dickson DW. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62:181\u201387.","journal-title":"Neurology"},{"key":"900_CR276","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pscychresns.2005.04.002","volume":"139","author":"JT O\u2019Brien","year":"2005","unstructured":"O\u2019Brien JT, Firbank MJ, Mosimann UP, Burn DJ, McKeith IG. Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res. 2005;139:79\u201388.","journal-title":"Psychiatry Res"},{"key":"900_CR277","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/brain\/awz069","volume":"142","author":"J Schumacher","year":"2019","unstructured":"Schumacher J, Peraza LR, Firbank M, Thomas AJ, Kaiser M, Gallagher P, O\u2019Brien JT, Blamire AM, Taylor JP. Dysfunctional brain dynamics and their origin in Lewy body dementia. Brain. 2019;142:1767\u201382.","journal-title":"Brain"},{"key":"900_CR278","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-019-0575-z","volume":"12","author":"E Chabran","year":"2020","unstructured":"Chabran E, Noblet V, Loureiro de Sousa P, Demuynck C, Philippi N, Mutter C, Anthony P, Martin-Hunyadi C, Cretin B, Blanc F. Changes in gray matter volume and functional connectivity in dementia with Lewy bodies compared to Alzheimer\u2019s disease and normal aging: implications for fluctuations. Alzheimers Res Ther. 2020;12:9.","journal-title":"Alzheimers Res Ther"},{"key":"900_CR279","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1017\/S1041610213001488","volume":"25","author":"JP Taylor","year":"2013","unstructured":"Taylor JP, Colloby SJ, McKeith IG, O\u2019Brien JT. Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in dementia with Lewy bodies. Int PsychogeriAtr. 2013;25:1917\u201328.","journal-title":"Int PsychogeriAtr"},{"key":"900_CR280","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pscychresns.2014.06.004","volume":"223","author":"ER Lowther","year":"2014","unstructured":"Lowther ER, O\u2019Brien JT, Firbank MJ, Blamire AM. Lewy body compared with Alzheimer dementia is associated with decreased functional connectivity in resting state networks. Psychiatry Res. 2014;223:192\u2013201.","journal-title":"Psychiatry Res"},{"key":"900_CR281","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.25453","volume":"85","author":"S Morbelli","year":"2019","unstructured":"Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, et al. Metabolic patterns across core features in dementia with Lewy bodies. Ann Neurol. 2019;85:715\u201325.","journal-title":"Ann Neurol"},{"key":"900_CR282","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41531-022-00279-x","volume":"8","author":"E Matar","year":"2022","unstructured":"Matar E, Ehgoetz Martens KA, Phillips JR, Wainstein G, Halliday GM, Lewis SJG, Shine JM. Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. NPJ Parkinsons Dis. 2022;8:16.","journal-title":"NPJ Parkinsons Dis"},{"key":"900_CR283","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.neurobiolaging.2012.09.015","volume":"34","author":"R Franciotti","year":"2013","unstructured":"Franciotti R, Falasca NW, Bonanni L, Anzellotti F, Maruotti V, Comani S, Thomas A, Tartaro A, Taylor JP, Onofrj M. Default network is not hypoactive in dementia with fluctuating cognition: an Alzheimer disease\/dementia with Lewy bodies comparison. Neurobiol Aging. 2013;34:1148\u201358.","journal-title":"Neurobiol Aging"},{"key":"900_CR284","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.nicl.2014.03.013","volume":"4","author":"LR Peraza","year":"2014","unstructured":"Peraza LR, Kaiser M, Firbank M, Graziadio S, Bonanni L, Onofrj M, Colloby SJ, Blamire A, O\u2019Brien J, Taylor JP. fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. neuroimage. Clin. 2014;4:558\u201365.","journal-title":"neuroimage. Clin"},{"key":"900_CR285","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/brain\/awz311","volume":"143","author":"E Matar","year":"2020","unstructured":"Matar E, Shine JM, Halliday GM, Lewis SJG. Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain. 2020;143:31\u201346.","journal-title":"Brain"},{"key":"900_CR286","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mds.29248","volume":"38","author":"A Habich","year":"2023","unstructured":"Habich A, Wahlund LO, Westman E, Dierks T, Ferreira D. (Dis-)connected dots in dementia with Lewy bodies-a systematic review of connectivity studies. Mov Disord. 2023;38:4\u201315.","journal-title":"Mov disord"},{"key":"900_CR287","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1093\/brain\/awm056","volume":"130","author":"BF Boeve","year":"2007","unstructured":"Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, Caselli RC, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130:2770\u201388.","journal-title":"Brain"},{"key":"900_CR288","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1113\/JP271324","volume":"594","author":"E Arrigoni","year":"2016","unstructured":"Arrigoni E, Chen MC, Fuller PM. The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep. J Physiol. 2016;594:5391\u2013414.","journal-title":"J Physiol"},{"key":"900_CR289","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1093\/brain\/awt152","volume":"136","author":"D Garc\u00eda-Lorenzo","year":"2013","unstructured":"Garc\u00eda-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, Leu-Semenescu S, Gallea C, Quattrocchi G, Pita Lobo P, Poupon C, Benali H, Arnulf I, et al. The coeruleus\/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson\u2019s disease. Brain. 2013;136:2120\u201329.","journal-title":"Brain"},{"key":"900_CR290","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/brain\/aww006","volume":"139","author":"M Ehrminger","year":"2016","unstructured":"Ehrminger M, Latimier A, Pyatigorskaya N, Garcia-Lorenzo D, Leu-Semenescu S, Vidailhet M, Lehericy S, Arnulf I. The coeruleus\/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain. 2016;139:1180\u201388.","journal-title":"Brain"},{"key":"900_CR291","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/mds.28895","volume":"37","author":"MG Garc\u00eda-Gomar","year":"2022","unstructured":"Garc\u00eda-Gomar MG, Videnovic A, Singh K, Stauder M, Lewis LD, Wald LL, Rosen BR, Bianciardi M. Disruption of brainstem structural connectivity in REM sleep behavior disorder using 7 Tesla magnetic resonance imaging. Mov Disord. 2022;37:847\u201353.","journal-title":"Mov disord"},{"key":"900_CR292","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mds.1120","volume":"16","author":"BF Boeve","year":"2001","unstructured":"Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16:622\u201330.","journal-title":"Mov disord"},{"key":"900_CR293","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1212\/WNL.0b013e31822c9148","volume":"77","author":"TJ Ferman","year":"2011","unstructured":"Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, Wszolek Z, Graff-Radford NR, Uitti R, Van Gerpen J, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77:875\u201382.","journal-title":"Neurology"},{"key":"900_CR294","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","volume":"14","author":"BF Boeve","year":"2013","unstructured":"Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14:754\u201362.","journal-title":"Sleep Med"},{"key":"900_CR295","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/mds.26347","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Adler CH, Dugger BN, Hentz JG, Shill HA, Driver-Dunckley E, Sabbagh MN, Jacobson SA, Belden CM, Sue LI, et al. REM sleep behavior disorder and neuropathology in Parkinson\u2019s disease. Mov Disord. 2015;30:1413\u201317.","journal-title":"Mov disord"},{"key":"900_CR296","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1212\/WNL.0000000000004496","volume":"89","author":"L Leclair-Visonneau","year":"2017","unstructured":"Leclair-Visonneau L, Clairembault T, Coron E, Le Dily S, Vavasseur F, Dalichampt M, P\u00e9r\u00e9on Y, Neunlist M, Derkinderen P. REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease. Neurology. 2017;89:1612\u201318.","journal-title":"Neurology"},{"key":"900_CR297","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1212\/01.wnl.0000298691.71637.96","volume":"70","author":"AM Schmeichel","year":"2008","unstructured":"Schmeichel AM, Buchhalter LC, Low PA, Parisi JE, Boeve BW, Sandroni P, Benarroch EE. Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology. 2008;70:368\u201373.","journal-title":"Neurology"},{"key":"900_CR298","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2990.2011.01203.x","volume":"38","author":"BN Dugger","year":"2012","unstructured":"Dugger BN, Murray ME, Boeve BF, Parisi JE, Benarroch EE, Ferman TJ, Dickson DW. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol Appl NeuroBiol. 2012;38:142\u201352.","journal-title":"Neuropathol Appl NeuroBiol"},{"key":"900_CR299","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fneur.2015.00190","volume":"6","author":"KP Grace","year":"2015","unstructured":"Grace KP, Horner RL. Evaluating the evidence surrounding pontine cholinergic involvement in REM Sleep generation. Front Neurol. 2015;6:190.","journal-title":"Front Neurol"},{"key":"900_CR300","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/brain\/awae069","volume":"147","author":"N Okkels","year":"2024","unstructured":"Okkels N, Grothe MJ, Taylor JP, Hasselbalch SG, Fedorova TD, Knudsen K, van der Zee S, van Laar T, Bohnen NI, Borghammer P, Horsager J. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain. 2024;147:2308\u201324.","journal-title":"Brain"},{"key":"900_CR301","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nature04767","volume":"441","author":"J Lu","year":"2006","unstructured":"Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature. 2006;441:589\u201394.","journal-title":"Nature"},{"key":"900_CR302","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/sleep\/34.4.419","volume":"34","author":"O Cl\u00e9ment","year":"2011","unstructured":"Cl\u00e9ment O, Sapin E, B\u00e9rod A, Fort P, Luppi PH. Evidence that neurons of the sublaterodorsal tegmental nucleus triggering paradoxical (REM) sleep are glutamatergic. Sleep. 2011;34:419\u201323.","journal-title":"Sleep"},{"key":"900_CR303","doi-asserted-by":"publisher","first-page":"10763","DOI":"10.1038\/ncomms10763","volume":"7","author":"J Cox","year":"2016","unstructured":"Cox J, Pinto L, Dan Y. Calcium imaging of sleep-wake related neuronal activity in the dorsal pons. Nat Commun. 2016;7:10763.","journal-title":"Nat Commun"},{"key":"900_CR304","doi-asserted-by":"publisher","first-page":"26782","DOI":"10.1038\/srep26782","volume":"6","author":"S Boucetta","year":"2016","unstructured":"Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT. Structural brain alterations associated with rapid eye movement Sleep behavior disorder in Parkinson\u2019s disease. Sci Rep. 2016;6:26782.","journal-title":"Sci Rep"},{"key":"900_CR305","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1016\/j.cub.2019.09.026","volume":"29","author":"ZA Torontali","year":"2019","unstructured":"Torontali ZA, Fraigne JJ, Sanghera P, Horner R, Peever J. The sublaterodorsal tegmental nucleus functions to couple brain state and motor activity during REM sleep and wakefulness. Curr Biol. 2019;29:3803\u201313.e 3805.","journal-title":"Curr Biol"},{"key":"900_CR306","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jnen\/61.5.413","volume":"61","author":"K Del Tredici","year":"2002","unstructured":"Del Tredici K, R\u00fcb, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413\u201326.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR307","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/bpa.12168","volume":"25","author":"K Seidel","year":"2015","unstructured":"Seidel K, Mahlke J, Siswanto S, Kr\u00fcger R, Heinsen H, Auburger G, Bouzrou M, Grinberg LT, Wicht H, Korf HW, et al. The brainstem pathologies of Parkinson\u2019s disease and dementia with Lewy bodies. Brain Pathol. 2015;25:121\u201335.","journal-title":"Brain Pathol"},{"key":"900_CR308","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/cne.23901","volume":"524","author":"K Taguchi","year":"2016","unstructured":"Taguchi K, Watanabe Y, Tsujimura A, Tanaka M. Brain region-dependent differential expression of alpha-synuclein. The J Comp Neurol. 2016;524:1236\u201358.","journal-title":"The J Comp Neurol"},{"key":"900_CR309","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1038\/s41467-020-17401-3","volume":"11","author":"H Feng","year":"2020","unstructured":"Feng H, Wen SY, Qiao QC, Pang YJ, Wang SY, Li HY, Cai J, Zhang KX, Chen J, Hu ZA, et al. Orexin signaling modulates synchronized excitation in the sublaterodorsal tegmental nucleus to stabilize REM sleep. Nat Commun. 2020;11:3661.","journal-title":"Nat Commun"},{"key":"900_CR310","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s11910-023-01322-x","volume":"23","author":"R Vetrivelan","year":"2023","unstructured":"Vetrivelan R, Bandaru SS. Neural control of REM sleep and motor atonia: current perspectives. Curr Neurol Neurosci Rep. 2023;23:907\u201323.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"900_CR311","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neulet.2014.03.020","volume":"569","author":"K Kasanuki","year":"2014","unstructured":"Kasanuki K, Iseki E, Kondo D, Fujishiro H, Minegishi M, Sato K, Katsuse O, Hino H, Kosaka K, Arai H. Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies. Neurosci Lett. 2014;569:68\u201373.","journal-title":"Neurosci Lett"},{"key":"900_CR312","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-014-0076-z","volume":"6","author":"TJ Ferman","year":"2014","unstructured":"Ferman TJ, Smith GE, Dickson DW, Graff-Radford NR, Lin SC, Wszolek Z, Van Gerpen JA, Uitti R, Knopman DS, Petersen RC, et al. Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer\u2019s disease using the multiple sleep latency test. Alzheimers Res Ther. 2014;6:76.","journal-title":"Alzheimers Res Ther"},{"key":"900_CR313","doi-asserted-by":"crossref","unstructured":"Abbott RD, Ross GW, Duda JE, Shin C, Uyehara-Lock JH, Masaki KH, Launer LJ, White LR, Tanner CM, Petrovitch H. Excessive daytime sleepiness and topographic expansion of Lewy pathology. Neurology. 2019 1432;93:e1425\u2013e.","DOI":"10.1212\/WNL.0000000000008241"},{"key":"900_CR314","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/pcn.13436","volume":"76","author":"M Mizutani","year":"2022","unstructured":"Mizutani M, Sano T, Ohira M, Takao M. Neuropathological studies of serotonergic and noradrenergic systems in Lewy body disease patients with delusion or depression. Psychiatry Clin Neurosci. 2022;76:459\u201367.","journal-title":"Psychiatry Clin Neurosci"},{"key":"900_CR315","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2021.4363","volume":"79","author":"DP Devanand","year":"2022","unstructured":"Devanand DP, Lee S, Huey ED, Goldberg TE. Associations between neuropsychiatric symptoms and neuropathological diagnoses of Alzheimer disease and related dementias. JAMA Psychiarty. 2022;79:359\u201367.","journal-title":"JAMA psychiarty"},{"key":"900_CR316","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1212\/WNL.0000000000005828","volume":"91","author":"K Kasanuki","year":"2018","unstructured":"Kasanuki K, Josephs KA, Ferman TJ, Murray ME, Koga S, Konno T, Sakae N, Parks A, Uitti RJ, Van Gerpen JA, et al. Diffuse Lewy body disease manifesting as corticobasal syndrome: a rare form of Lewy body disease. Neurology. 2018;91:e268\u201379.","journal-title":"Neurology"},{"key":"900_CR317","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ana.25979","volume":"89","author":"M Buciuc","year":"2021","unstructured":"Buciuc M, Whitwell JL, Kasanuki K, Graff-Radford J, Machulda MM, Duffy JR, Strand EA, Lowe VJ, Graff-Radford NR, Rush BK, et al. Lewy body disease is a contributor to logopenic progressive aphasia phenotype. Ann Neurol. 2021;89:520\u201333.","journal-title":"Ann Neurol"},{"issue":"Suppl, 3","key":"900_CR318","doi-asserted-by":"publisher","first-page":"Iii\/1","DOI":"10.1007\/s00415-002-1301-4","volume":"249","author":"H Braak","year":"2002","unstructured":"Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, R\u00fcb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson\u2019s disease (preclinical and clinical stages). J Neurol. 2002;249(Suppl, 3):Iii\/1\u20135.","journal-title":"J Neurol"},{"key":"900_CR319","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak H, R\u00fcb U, Gai WP. Del Tredici K. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003;110:517\u201336.","journal-title":"J Neural Transm (Vienna)"},{"key":"900_CR320","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bj\u00f6rklund A, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501\u201303.","journal-title":"Nat Med"},{"key":"900_CR321","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14:504\u201306.","journal-title":"Nat Med"},{"key":"900_CR322","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/mds.22369","volume":"23","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008;23:2303\u201306.","journal-title":"Mov disord"},{"key":"900_CR323","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, Lee VM. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949\u201353.","journal-title":"Science"},{"key":"900_CR324","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. Prion-like spreading of pathological \u03b1-synuclein in brain. Brain. 2013;136:1128\u201338.","journal-title":"Brain"},{"key":"900_CR325","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens A, Dehay B, Bov\u00e9 J, Carballo-Carbajal I, Dovero S, P\u00e9rez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, et al. Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75:351\u201362.","journal-title":"Ann Neurol"},{"key":"900_CR326","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","volume":"5","author":"A Shimozawa","year":"2017","unstructured":"Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M, Higuchi M, Yanai K, Hisanaga SI, Hasegawa M. Propagation of pathological \u03b1-synuclein in marmoset brain. Acta Neuropathol Commun. 2017;5:12.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR327","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron. 2019;103:627\u201341.e627.","journal-title":"Neuron"},{"key":"900_CR328","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/brain\/awab061","volume":"144","author":"N Van Den Berge","year":"2021","unstructured":"Van Den Berge N, Ferreira N, Mikkelsen TW, Alstrup AKO, Tamg\u00fcney, Karlsson P, Terkelsen AJ, Nyengaard JR, Jensen PH, Borghammer P. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain. 2021;144:1853\u201368.","journal-title":"Brain"},{"key":"900_CR329","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1084\/jem.20160368","volume":"213","author":"NL Rey","year":"2016","unstructured":"Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P. Widespread transneuronal propagation of \u03b1-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson\u2019s disease. J Exp Med. 2016;213:1759\u201378.","journal-title":"J Exp Med"},{"key":"900_CR330","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1792-9","volume":"135","author":"NL Rey","year":"2018","unstructured":"Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ, Lee VM, Brundin P. Spread of aggregates after olfactory bulb injection of \u03b1-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol. 2018;135:65\u201383.","journal-title":"Acta Neuropathol"},{"key":"900_CR331","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/mds.28512","volume":"36","author":"N Uemura","year":"2021","unstructured":"Uemura N, Ueda J, Yoshihara T, Ikuno M, Uemura MT, Yamakado H, Asano M, Trojanowski JQ, Takahashi R. \u03b1-synuclein spread from olfactory bulb causes hyposmia, anxiety, and memory loss in BAC-SNCA mice. Mov Disord. 2021;36:2036\u201347.","journal-title":"Mov disord"},{"key":"900_CR332","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/mds.29161","volume":"37","author":"M Sawamura","year":"2022","unstructured":"Sawamura M, Onoe H, Tsukada H, Isa K, Yamakado H, Okuda S, Ikuno M, Hatanaka Y, Murayama S, Uemura N, et al. Lewy body disease Primate Model with \u03b1-Synuclein propagation from the olfactory bulb. Mov Disord. 2022;37:2033\u201344.","journal-title":"Mov disord"},{"key":"900_CR333","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00702-018-1898-9","volume":"126","author":"KA Jellinger","year":"2019","unstructured":"Jellinger KA. Is Braak staging valid for all types of Parkinson\u2019s disease? J Neural Transm (Vienna). 2019;126:423\u201331.","journal-title":"J Neural Transm (Vienna)"},{"key":"900_CR334","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00401-019-02071-3","volume":"138","author":"A Raunio","year":"2019","unstructured":"Raunio A, Kaivola K, Tuimala J, Kero M, Oinas M, Polvikoski T, Paetau A, Tienari PJ, Myllykangas L. Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of finns aged 85. Acta Neuropathol. 2019;138:771\u201382.","journal-title":"Acta Neuropathol"},{"key":"900_CR335","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/0016-5085(84)90079-9","volume":"87","author":"SJ Qualman","year":"1984","unstructured":"Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson\u2019s disease. Gastroenterology. 1984;87:848\u201356.","journal-title":"Gastroenterology"},{"key":"900_CR336","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00687767","volume":"76","author":"K Wakabayashi","year":"1988","unstructured":"Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson\u2019s disease: the presence of Lewy bodies in Auerbach\u2019s and Meissner\u2019s plexuses. Acta Neuropathol. 1988;76:217\u201321.","journal-title":"Acta Neuropathol"},{"key":"900_CR337","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ana.24518","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson E, Horv\u00e1th-Puh\u00f3 E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, S\u00f8rensen HT. Does vagotomy reduce the risk of Parkinson\u2019s disease: the authors reply. Ann Neurol. 2015;78:1012\u201313.","journal-title":"Ann Neurol"},{"key":"900_CR338","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1212\/WNL.0000000000003961","volume":"88","author":"B Liu","year":"2017","unstructured":"Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, Wirdefeldt K. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology. 2017;88:1996\u20132002.","journal-title":"Neurology"},{"key":"900_CR339","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.25020","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? Evidence from 3 cases. Mov Disord. 2012;27:716\u201319.","journal-title":"Mov disord"},{"key":"900_CR340","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-013-1214-6","volume":"127","author":"D Hilton","year":"2014","unstructured":"Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C. Accumulation of \u03b1-synuclein in the bowel of patients in the pre-clinical phase of Parkinson\u2019s disease. Acta Neuropathol. 2014;127:235\u201341.","journal-title":"Acta Neuropathol"},{"key":"900_CR341","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","volume":"79","author":"MG Stokholm","year":"2016","unstructured":"Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological \u03b1-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016;79:940\u201349.","journal-title":"Ann Neurol"},{"key":"900_CR342","doi-asserted-by":"crossref","unstructured":"Beck G, Hori Y, Hayashi Y, Morii E, Takehara T, Mochizuki H. Detection of phosphorylated alpha-synuclein in the muscularis propria of the gastrointestinal tract is a sensitive predictor for Parkinson\u2019s disease. Parkinsons Dis. 2020;4687530.","DOI":"10.1155\/2020\/4687530"},{"key":"900_CR343","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/neup.12189","volume":"35","author":"TG Beach","year":"2015","unstructured":"Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, Lue L, Roher AE, Dugger BN, Maarouf C, et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology. 2015;35:354\u201389.","journal-title":"Neuropathology"},{"key":"900_CR344","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mds.26605","volume":"31","author":"CH Adler","year":"2016","unstructured":"Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson\u2019s disease. Mov Disord. 2016;31:1114\u201319.","journal-title":"Mov disord"},{"key":"900_CR345","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3233\/JPD-212733","volume":"11","author":"TG Beach","year":"2021","unstructured":"Beach TG, Adler CH, Sue LI, Shill HA, Driver-Dunckley E, Mehta SH, Intorcia AJ, Glass MJ, Walker JE, Arce R, et al. Vagus nerve and stomach synucleinopathy in Parkinson\u2019s disease, incidental Lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d hypothesis. J Parkinsons Dis. 2021;11:1833\u201343.","journal-title":"J Parkinsons Dis"},{"key":"900_CR346","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1097\/NEN.0b013e31818b4126","volume":"67","author":"R Sengoku","year":"2008","unstructured":"Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, Arai T, Sawabe M, Tanaka N, Mochizuki H, et al. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol. 2008;67:1072\u201383.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR347","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/mds.22775","volume":"24","author":"Y Miki","year":"2009","unstructured":"Miki Y, Mori F, Wakabayashi K, Kuroda N, Orimo S. Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord. 2009;24:2299\u2013301.","journal-title":"Mov disord"},{"key":"900_CR348","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","volume":"33","author":"CH Hawkes","year":"2007","unstructured":"Hawkes CH, Del Tredici K, Braak H. Parkinson\u2019s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33:599\u2013614.","journal-title":"Neuropathol Appl neurobiol"},{"key":"900_CR349","doi-asserted-by":"crossref","unstructured":"Hawkes CH, Del Tredici K, Braak H. Parkinson\u2019s disease: the dual hit theory revisited. Ann N Y Acad Sci. 2009, 1170;615\u201322.","DOI":"10.1111\/j.1749-6632.2009.04365.x"},{"key":"900_CR350","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Del Tredici","year":"2016","unstructured":"Del Tredici K, Braak H. Review: sporadic Parkinson\u2019s disease: development and distribution of \u03b1-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42:33\u201350.","journal-title":"Neuropathol Appl neurobiol"},{"key":"900_CR351","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer P, Van Den Berge N. Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. J Parkinsons Dis. 2019;9:S281\u2013s295.","journal-title":"J Parkinsons Dis"},{"key":"900_CR352","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3233\/JPD-202481","volume":"11","author":"P Borghammer","year":"2021","unstructured":"Borghammer P. The \u03b1-Synuclein origin and connectome Model (SOC Model) of Parkinson\u2019s disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J Parkinsons Dis. 2021;11:455\u201374.","journal-title":"J Parkinsons Dis"},{"key":"900_CR353","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","volume":"161","author":"P Borghammer","year":"2021","unstructured":"Borghammer P, Horsager J, Andersen K, Van Den Berge N, Raunio A, Murayama S, Parkkinen L, Myllykangas L. Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiol Dis. 2021;161:105557.","journal-title":"Neurobiol Dis"},{"key":"900_CR354","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41531-022-00436-2","volume":"8","author":"P Borghammer","year":"2022","unstructured":"Borghammer P, Just MK, Horsager J, Skj\u00e6rb\u00e6k C, Raunio A, Kok EH, Savola S, Murayama S, Saito Y, Myllykangas L, Van Den Berge N. A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8:166.","journal-title":"NPJ Parkinsons Dis"},{"key":"900_CR355","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","volume":"130","author":"P Borghammer","year":"2023","unstructured":"Borghammer P. The brain-first vs. body-first model of Parkinson\u2019s disease with comparison to alternative models. J Neural Transm (Vienna). 2023;130:737\u201353.","journal-title":"J Neural Transm (Vienna)"},{"key":"900_CR356","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-015-1485-1","volume":"131","author":"T Uchihara","year":"2016","unstructured":"Uchihara T, Giasson BI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131:49\u201373.","journal-title":"Acta Neuropathol"},{"key":"900_CR357","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/neup.12348","volume":"37","author":"T Uchihara","year":"2017","unstructured":"Uchihara T. An order in Lewy body disorders: retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal\/multifocal Lewy body disease. Neuropathology. 2017;37:129\u201349.","journal-title":"Neuropathology"},{"key":"900_CR358","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tins.2016.10.008","volume":"40","author":"S Engelender","year":"2017","unstructured":"Engelender S, Isacson O. The threshold theory for Parkinson\u2019s disease. Trends Neurosci. 2017;40:4\u201314.","journal-title":"Trends Neurosci"},{"key":"900_CR359","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1523\/JNEUROSCI.1787-16.2017","volume":"37","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Obeso JA, Halliday GM. Parkinson\u2019s disease is not simply a prion disorder. J Neurosci. 2017;37:9799\u2013807.","journal-title":"J. neurosci"},{"key":"900_CR360","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/bs.pbr.2020.02.005","volume":"252","author":"P Gonzalez-Rodriguez","year":"2020","unstructured":"Gonzalez-Rodriguez P, Zampese E, Surmeier DJ. Selective neuronal vulnerability in Parkinson\u2019s disease. Prog Brain Res. 2020;252:61\u201389.","journal-title":"Prog Brain Res"},{"key":"900_CR361","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/neup.12691","volume":"40","author":"K Wakabayashi","year":"2020","unstructured":"Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson\u2019s disease. Neuropathology. 2020;40:415\u201325.","journal-title":"Neuropathology"},{"key":"900_CR362","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S1474-4422(10)70213-1","volume":"9","author":"E Angot","year":"2010","unstructured":"Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? The Lancet Neurol. 2010;9:1128\u201338.","journal-title":"The Lancet Neurol"},{"key":"900_CR363","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.arr.2019.01.012","volume":"50","author":"JY Vargas","year":"2019","unstructured":"Vargas JY, Grudina C, Zurzolo C. The prion-like spreading of \u03b1-synuclein: from in vitro to in vivo models of Parkinson\u2019s disease. Ageing Res Rev. 2019;50:89\u2013101.","journal-title":"Ageing Res Rev"},{"key":"900_CR364","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41582-024-01043-w","volume":"21","author":"H Park","year":"2025","unstructured":"Park H, Kam TI, Dawson VL, Dawson TM. \u03b1-Synuclein pathology as a target in neurodegenerative diseases. Nat Rev Neurol. 2025;21:32\u201347.","journal-title":"Nat Rev Neurol"},{"key":"900_CR365","doi-asserted-by":"publisher","first-page":"104905","DOI":"10.1016\/j.neures.2025.04.008","volume":"216","author":"N Uemura","year":"2025","unstructured":"Uemura N. Fibril-seeded animal models of synucleinopathies: pathological mechanisms, disease modeling, and therapeutic implications. Neurosci Res. 2025;216:104905.","journal-title":"Neurosci Res"},{"key":"900_CR366","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk KC, Song C, O\u2019Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA. 2009;106:20051\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR367","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","volume":"111","author":"KM Danzer","year":"2009","unstructured":"Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J NeuroChem. 2009;111:192\u2013203.","journal-title":"J NeuroChem"},{"key":"900_CR368","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1471-2202-15-69","volume":"15","author":"S Auli\u0107","year":"2014","unstructured":"Auli\u0107 S, Le TT, Moda F, Abounit S, Corvaglia S, Casalis L, Gustincich S, Zurzolo C, Tagliavini F, Legname G. Defined \u03b1-synuclein prion-like molecular assemblies spreading in cell culture. BMC Neurosci. 2014;15:69.","journal-title":"BMC NeuroSci"},{"key":"900_CR369","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","volume":"106","author":"P Desplats","year":"2009","unstructured":"Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA. 2009;106:13010\u201315.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR370","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm VM, Zhang B, O\u2019Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J Exp Med. 2012;209:975\u201386.","journal-title":"J Exp Med"},{"key":"900_CR371","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","volume":"294","author":"TR Yamasaki","year":"2019","unstructured":"Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI. Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics. J Biol Chem. 2019;294:1045\u201358.","journal-title":"J Biol Chem"},{"key":"900_CR372","doi-asserted-by":"crossref","unstructured":"Ayers JI, Lee J, Monteiro O, Woerman AL, Lazar AA, Condello C, Paras NA, Prusiner SB. Different \u03b1-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Natl Acad Sci USA. 2022;119.","DOI":"10.1073\/pnas.2113489119"},{"key":"900_CR373","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","volume":"23","author":"A Lau","year":"2020","unstructured":"Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC, Stuart E, Menon S, Visanji NP, Meisl G, et al. \u03b1-Synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23:21\u201331.","journal-title":"Nat neurosci"},{"key":"900_CR374","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00401-022-02425-4","volume":"143","author":"GM Lloyd","year":"2022","unstructured":"Lloyd GM, Sorrentino ZA, Quintin S, Gorion KM, Bell BM, Paterno G, Long B, Prokop S, Giasson BI. Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human \u03b1-synuclein transgenic mice. Acta Neuropathol. 2022;143:663\u201385.","journal-title":"Acta Neuropathol"},{"key":"900_CR375","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2022.12.012","volume":"109","author":"J Zhang","year":"2023","unstructured":"Zhang J, Han J, Shi Z, Zhang J, Zhou Z, Liu J, Yang G, Sun Y, Gu P, Zhao P, et al. The characteristic of nonmotor symptoms with different phenotypes and onsets in multiple system atrophy patients. J Clin Neurosci. 2023;109:1\u20135.","journal-title":"J Clin neurosci"},{"key":"900_CR376","doi-asserted-by":"publisher","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","volume":"112","author":"SB Prusiner","year":"2015","unstructured":"Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, et al. Evidence for \u03b1-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA. 2015;112:E5308\u20135317.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR377","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"V der Perren A","year":"2020","unstructured":"der Perren A V, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, den Haute C V, Gentleman S, Melki R, Baekelandt V. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139:977\u20131000.","journal-title":"Acta Neuropathol"},{"key":"900_CR378","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","volume":"9","author":"AL Young","year":"2018","unstructured":"Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat Commun. 2018;9:4273.","journal-title":"Nat Commun"},{"key":"900_CR379","doi-asserted-by":"publisher","first-page":"613261","DOI":"10.3389\/frai.2021.613261","volume":"4","author":"AL Young","year":"2021","unstructured":"Young AL, Vogel JW, Aksman LM, Wijeratne PA, Eshaghi A, Oxtoby NP, Williams SCR, Alexander DC. Ordinal SuStaIn: subtype and stage inference for clinical scores, visual ratings, and other ordinal data. Front Artif Intell. 2021;4:613261.","journal-title":"Front Artif Intell"},{"key":"900_CR380","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27:871\u201381.","journal-title":"Nat Med"},{"key":"900_CR381","doi-asserted-by":"publisher","first-page":"e941","DOI":"10.1212\/WNL.0000000000012410","volume":"97","author":"AL Young","year":"2021","unstructured":"Young AL, Bocchetta M, Russell LL, Convery RS, Peakman G, Todd E, Cash DM, Greaves CV, van Swieten J, Jiskoot L, et al. Characterizing the clinical features and atrophy patterns of MAPT-related frontotemporal dementia with disease progression modeling. Neurology. 2021;97:e941\u201352.","journal-title":"Neurology"},{"key":"900_CR382","doi-asserted-by":"publisher","first-page":"814768","DOI":"10.3389\/fneur.2022.814768","volume":"13","author":"Y Saito","year":"2022","unstructured":"Saito Y, Kamagata K, Wijeratne PA, Andica C, Uchida W, Takabayashi K, Fujita S, Akashi T, Wada A, Shimoji K, et al. Temporal progression patterns of brain atrophy in corticobasal syndrome and progressive supranuclear palsy revealed by subtype and stage inference (SuStain). Front Neurol. 2022;13:814768.","journal-title":"Front Neurol"},{"key":"900_CR383","doi-asserted-by":"crossref","unstructured":"Collij LE, Salvad\u00f3 G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, Aksman L, Wink AM, Berckel BNM, van de Flier WM, et al. Spatial-temporal patterns of \u03b2-amyloid accumulation: a subtype and stage inference model analysis. Neurology. 2022 1703;98:e1692\u2013e.","DOI":"10.1212\/WNL.0000000000200148"},{"key":"900_CR384","doi-asserted-by":"publisher","first-page":"fcac098","DOI":"10.1093\/braincomms\/fcac098","volume":"4","author":"WJ Scotton","year":"2022","unstructured":"Scotton WJ, Bocchetta M, Todd E, Cash DM, Oxtoby N, VandeVrede L, Heuer H, Alexander DC, Rowe JB, Morris HR, et al. A data-driven model of brain volume changes in progressive supranuclear palsy. Brain Commun. 2022;4:fcac098.","journal-title":"Brain Commun"},{"key":"900_CR385","doi-asserted-by":"publisher","first-page":"fcad048","DOI":"10.1093\/braincomms\/fcad048","volume":"5","author":"WJ Scotton","year":"2023","unstructured":"Scotton WJ, Shand C, Todd E, Bocchetta M, Cash DM, VandeVrede L, Heuer H, Young AL, Oxtoby N, Alexander DC, et al. Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning. Brain Commun. 2023;5:fcad048.","journal-title":"Brain Commun"},{"key":"900_CR386","doi-asserted-by":"publisher","first-page":"104835","DOI":"10.1016\/j.ebiom.2023.104835","volume":"97","author":"J Hong","year":"2023","unstructured":"Hong J, Lu J, Liu F, Wang M, Li X, Clement C, Lopes L, Brendel M, Rominger A, Yen TC, et al. Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [(18)F]Florzolotau PET imaging and subtype\/stage inference algorithm. EBioMedicine. 2023;97:104835.","journal-title":"EBioMedicine"},{"key":"900_CR387","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41531-023-00556-3","volume":"9","author":"C Zhou","year":"2023","unstructured":"Zhou C, Wang L, Cheng W, Lv J, Guan X, Guo T, Wu J, Zhang W, Gao T, Liu X, et al. Two distinct trajectories of clinical and neurodegeneration events in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9:111.","journal-title":"NPJ Parkinsons Dis"},{"key":"900_CR388","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1093\/brain\/awae303","volume":"147","author":"Y Sakato","year":"2024","unstructured":"Sakato Y, Shima A, Terada Y, Takeda K, Sakamaki-Tsukita H, Nishida A, Yoshimura K, Wada I, Furukawa K, Kambe D, et al. Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson\u2019s disease. Brain. 2024;147:3702\u201313.","journal-title":"Brain"},{"key":"900_CR389","doi-asserted-by":"crossref","unstructured":"Satoh R, Sekiya H, Ali F, Clark HM, Utianski RL, Duffy JR, Machulda MM, Dickson DW, Josephs KA, Whitwell JL. Uncovering image-driven subtypes with distinct pathology and clinical course in autopsy-confirmed four repeat Tauopathies. Ann Neurol. 2025.","DOI":"10.1002\/ana.27286"},{"key":"900_CR390","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/brain\/awad145","volume":"146","author":"AL Young","year":"2023","unstructured":"Young AL, Vogel JW, Robinson JL, McMillan CT, Ossenkoppele R, Wolk DA, Irwin DJ, Elman L, Grossman M, Lee VMY, et al. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies. Brain. 2023;146:2975\u201388.","journal-title":"Brain"},{"key":"900_CR391","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1038\/s41467-024-49402-x","volume":"15","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek SE, Vogel JW, Collij LE, Serrano GE, Tremblay C, Young AL, Arce RA, Shill HA, Driver-Dunckley ED, Mehta SH, et al. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type \u03b1-synuclein pathology. Nat Commun. 2024;15:5133.","journal-title":"Nat Commun"},{"key":"900_CR392","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40478-025-01944-x","volume":"13","author":"M Otero-Jimenez","year":"2025","unstructured":"Otero-Jimenez M, Wojewska MJ, Binding LP, Jogaudaite S, Gray-Rodriguez S, Young AL, Gentleman S, Alegre-Abarrategui J. Neuropathological stages of neuronal, astrocytic and oligodendrocytic alpha-synuclein pathology in Parkinson\u2019s disease. Acta Neuropathol Commun. 2025;13:25.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR393","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41593-025-01910-9","volume":"28","author":"KB Andersen","year":"2025","unstructured":"Andersen KB, Krishnamurthy A, Just MK, Van Den Berge N, Skj\u00e6rb\u00e6k C, Horsager J, Knudsen K, Vogel JW, Toledo JB, Attems J, et al. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals. Nat Neurosci. 2025;28:925\u201336.","journal-title":"Nat neurosci"},{"key":"900_CR394","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1021\/acs.chemrev.0c01122","volume":"121","author":"PH Nguyen","year":"2021","unstructured":"Nguyen PH, Ramamoorthy A, Sahoo BR, Zheng J, Faller P, Straub JE, Dominguez L, Shea JE, Dokholyan NV, De Simone A, et al. Amyloid oligomers: a joint Experimental\/Computational perspective on Alzheimer\u2019s disease, Parkinson\u2019s disease, type II diabetes, and amyotrophic lateral sclerosis. Chem Rev. 2021;121:2545\u2013647.","journal-title":"Chem Rev"},{"key":"900_CR395","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108:4194\u201399.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR396","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, et al. Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell. 2012;149:1048\u201359.","journal-title":"Cell"},{"key":"900_CR397","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1021\/bi0102398","volume":"40","author":"MJ Volles","year":"2001","unstructured":"Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson\u2019s disease. Biochemistry. 2001;40:7812\u201319.","journal-title":"Biochemistry"},{"key":"900_CR398","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","volume":"27","author":"KM Danzer","year":"2007","unstructured":"Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27:9220\u201332.","journal-title":"J. neurosci"},{"key":"900_CR399","first-page":"E1994","volume":"112","author":"SW Chen","year":"2015","unstructured":"Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, et al. Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation. Proc Natl Acad Sci USA. 2015;112:E1994\u20132003.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR400","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1242\/jcs.180737","volume":"129","author":"PR Angelova","year":"2016","unstructured":"Angelova PR, Ludtmann MH, Horrocks MH, Negoda A, Cremades N, Klenerman D, Dobson CM, Wood NW, Pavlov EV, Gandhi S, Abramov AY. Ca2+ is a key factor in \u03b1-synuclein-induced neurotoxicity. J Cell Sci. 2016;129:1792\u2013801.","journal-title":"J Cell Sci"},{"key":"900_CR401","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1113\/JP271968","volume":"594","author":"TJ Kaufmann","year":"2016","unstructured":"Kaufmann TJ, Harrison PM, Richardson MJ, Pinheiro TJ, Wall MJ. Intracellular soluble \u03b1-synuclein oligomers reduce pyramidal cell excitability. J Physiol. 2016;594:2751\u201372.","journal-title":"J Physiol"},{"key":"900_CR402","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1021\/acs.langmuir.6b02572","volume":"32","author":"H Chaudhary","year":"2016","unstructured":"Chaudhary H, Iyer A, Subramaniam V, Claessens MM. \u03b1-Synuclein oligomers stabilize pre-existing defects in supported bilayers and propagate membrane damage in a fractal-like pattern. Langmuir. 2016;32:11827\u201336.","journal-title":"Langmuir"},{"key":"900_CR403","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, Cecchi C, Vendruscolo M, Chiti F, Cremades N, et al. Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Science. 2017;358:1440\u201343.","journal-title":"Science"},{"key":"900_CR404","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1021\/acschembio.9b00324","volume":"14","author":"M Vivoli Vega","year":"2019","unstructured":"Vivoli Vega M, Cascella R, Chen SW, Fusco G, De Simone A, Dobson CM, Cecchi C, Chiti F. The toxicity of misfolded protein oligomers is Independent of their secondary structure. ACS Chem Biol. 2019;14:1593\u2013600.","journal-title":"ACS Chem Biol"},{"key":"900_CR405","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1038\/s41467-021-21937-3","volume":"12","author":"R Cascella","year":"2021","unstructured":"Cascella R, Chen SW, Bigi A, Camino JD, Xu CK, Dobson CM, Chiti F, Cremades N, Cecchi C. The release of toxic oligomers from \u03b1-synuclein fibrils induces dysfunction in neuronal cells. Nat Commun. 2021;12:1814.","journal-title":"Nat Commun"},{"key":"900_CR406","doi-asserted-by":"publisher","first-page":"17469","DOI":"10.1021\/acsnano.3c10889","volume":"18","author":"G \u0160neiderien\u0117","year":"2024","unstructured":"\u0160neiderien\u0117 G, Czekalska MA, Xu CK, Jayaram AK, Krainer G, Arter WE, Peter QAE, Castellana-Cruz M, Saar KL, Levin A, et al. \u03b1-Synuclein oligomers displace monomeric \u03b1-Synuclein from lipid membranes. ACS Nano. 2024;18:17469\u201382.","journal-title":"ACS Nano"},{"key":"900_CR407","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbrc.2007.02.163","volume":"356","author":"L Chen","year":"2007","unstructured":"Chen L, Jin J, Davis J, Zhou Y, Wang Y, Liu J, Lockhart PJ, Zhang J. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun. 2007;356:548\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"900_CR408","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","volume":"486","author":"SJ Chinta","year":"2010","unstructured":"Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial \u03b1-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486:235\u201339.","journal-title":"Neurosci Lett"},{"key":"900_CR409","doi-asserted-by":"publisher","first-page":"21490","DOI":"10.1074\/jbc.M113.545749","volume":"289","author":"ES Luth","year":"2014","unstructured":"Luth ES, Stavrovskaya IG, Bartels T, Kristal BS, Selkoe DJ. Soluble, prefibrillar \u03b1-synuclein oligomers promote complex I-dependent, Ca2\u00b1induced mitochondrial dysfunction. J Biol Chem. 2014;289:21490\u2013507.","journal-title":"J Biol Chem"},{"key":"900_CR410","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.bbagen.2014.02.013","volume":"1840","author":"N Plotegher","year":"2014","unstructured":"Plotegher N, Gratton E, Bubacco L. Number and brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim Biophys Acta. 2014;1840:2014\u201324.","journal-title":"Biochim Biophys Acta"},{"key":"900_CR411","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mcn.2017.04.009","volume":"82","author":"V Lindstr\u00f6m","year":"2017","unstructured":"Lindstr\u00f6m V, Gustafsson G, Sanders LH, Howlett EH, Sigvardson J, Kasrayan A, Ingelsson M, Bergstr\u00f6m J, Erlandsson A. Extensive uptake of \u03b1-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol Cell Neurosci. 2017;82:143\u201356.","journal-title":"Mol Cell neurosci"},{"key":"900_CR412","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY, Berezhnov AV, Yao Z, Little D, Banushi B, et al. \u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun. 2018;9:2293.","journal-title":"Nat Commun"},{"key":"900_CR413","doi-asserted-by":"publisher","first-page":"11750","DOI":"10.1523\/JNEUROSCI.0234-12.2012","volume":"32","author":"MJ Di\u00f3genes","year":"2012","unstructured":"Di\u00f3genes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, Guerreiro P, N\u00e4sstr\u00f6m T, Franquelim HG, Oliveira LM, Castanho MA, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012;32:11750\u201362.","journal-title":"J. neurosci"},{"key":"900_CR414","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1073\/pnas.1218424110","volume":"110","author":"BK Choi","year":"2013","unstructured":"Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, Lee NK, Shin YK. Large \u03b1-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA. 2013;110:4087\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR415","doi-asserted-by":"publisher","first-page":"21742","DOI":"10.1074\/jbc.M113.451815","volume":"288","author":"I Prots","year":"2013","unstructured":"Prots I, Veber V, Brey S, Campioni S, Buder K, Riek R, B\u00f6hm KJ, Winner B. \u03b1-synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem. 2013;288:21742\u201354.","journal-title":"J Biol Chem"},{"key":"900_CR416","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/brain\/awu057","volume":"137","author":"E Rockenstein","year":"2014","unstructured":"Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, et al. Accumulation of oligomer-prone \u03b1-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain. 2014;137:1496\u2013513.","journal-title":"Brain"},{"key":"900_CR417","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/nn.4648","volume":"20","author":"DG Ferreira","year":"2017","unstructured":"Ferreira DG, Temido-Ferreira M, Vicente Miranda H, Batalha VL, Coelho JE, \u00c9 M S, Marques-Morgado I, Vaz SH, Rhee JS, Schmitz M, et al. \u03b1-synuclein interacts with PrP(C) to induce cognitive impairment through mGlur5 and NMDAR2B. Nat Neurosci. 2017;20:1569\u201379.","journal-title":"Nat neurosci"},{"key":"900_CR418","doi-asserted-by":"publisher","first-page":"40699","DOI":"10.1038\/srep40699","volume":"7","author":"N Plotegher","year":"2017","unstructured":"Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, Greggio E, Bisaglia M, Veronesi M, Girotto S, et al. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep. 2017;7:40699.","journal-title":"Sci Rep"},{"key":"900_CR419","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/brain\/awz065","volume":"142","author":"V Durante","year":"2019","unstructured":"Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M, Paciotti S, Quiroga-Varela A, Chiasserini D, Mellone M, Mazzocchetti P, et al. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain. 2019;142:1365\u201385.","journal-title":"Brain"},{"key":"900_CR420","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1750-1326-5-56","volume":"5","author":"P Jiang","year":"2010","unstructured":"Jiang P, Gan M, Ebrahim AS, Lin WL, Melrose HL, Yen SH. ER stress response plays an important role in aggregation of \u03b1-synuclein. Mol Neurodegener. 2010;5:56.","journal-title":"Mol NeurodeGener"},{"key":"900_CR421","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1523\/JNEUROSCI.5367-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, Schneider BL, Lee MK. Endoplasmic reticulum stress is important for the manifestations of \u03b1-synucleinopathy in vivo. J Neurosci. 2012;32:3306\u201320.","journal-title":"J. neurosci"},{"key":"900_CR422","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1523\/JNEUROSCI.5368-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic \u03b1-synuclein oligomer within endoplasmic reticulum occurs in \u03b1-synucleinopathy in vivo. J Neurosci. 2012;32:3301\u201305.","journal-title":"J. neurosci"},{"key":"900_CR423","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s11064-012-0780-7","volume":"37","author":"DL Castillo-Carranza","year":"2012","unstructured":"Castillo-Carranza DL, Zhang Y, Guerrero-Mu\u00f1oz MJ, Kayed R, Rincon-Limas DE, Fernandez-Funez P. Differential activation of the ER stress factor XBP1 by oligomeric assemblies. Neurochem Res. 2012;37:1707\u201317.","journal-title":"Neurochem Res"},{"key":"900_CR424","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-018-1907-y","volume":"137","author":"CD Hughes","year":"2019","unstructured":"Hughes CD, Choi ML, Ryten M, Hopkins L, Drews A, Bot\u00eda JA, Iljina M, Rodrigues M, Gagliano SA, Gandhi S, et al. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson\u2019s disease pathogenesis. Acta Neuropathol. 2019;137:103\u201320.","journal-title":"Acta Neuropathol"},{"key":"900_CR425","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson\u2019s disease. Faseb J. 2005;19:533\u201342.","journal-title":"Faseb J"},{"key":"900_CR426","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/039463200902200405","volume":"22","author":"H Wilms","year":"2009","unstructured":"Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Sch\u00e4fer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, et al. Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int J Immunopathol Pharmacol. 2009;22:897\u2013909.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"900_CR427","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.","journal-title":"Nat Commun"},{"key":"900_CR428","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Nishimura Y, Matsuse D, Sekiya H, Masaki K, Tanaka T, Saiga T, Harada M, Kira YI, Dickson DW, et al. A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of \u03b1-synuclein oligomers and phosphorylated \u03b1-synuclein aggregates. Brain Behav Immun. 2024.","DOI":"10.1016\/j.bbi.2024.07.004"},{"key":"900_CR429","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/awn349","volume":"132","author":"KE Paleologou","year":"2009","unstructured":"Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain. 2009;132:1093\u2013101.","journal-title":"Brain"},{"key":"900_CR430","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM. Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75:1766\u201372.","journal-title":"Neurology"},{"key":"900_CR431","doi-asserted-by":"publisher","first-page":"e0196056","DOI":"10.1371\/journal.pone.0196056","volume":"13","author":"LB Lassen","year":"2018","unstructured":"Lassen LB, Gregersen E, Isager AK, Betzer C, Kofoed RH, Jensen PH. ELISA method to detect \u03b1-synuclein oligomers in cell and animal models. PLoS One. 2018;13:e0196056.","journal-title":"PLoS One"},{"key":"900_CR432","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1039\/D2AY00611A","volume":"14","author":"Z Saedi","year":"2022","unstructured":"Saedi Z, Nikkhah M. A FRET-based aptasensor for the detection of \u03b1-synuclein oligomers as biomarkers of Parkinson\u2019s disease. Anal Methods. 2022;14:2937\u201344.","journal-title":"Anal Methods"},{"key":"900_CR433","doi-asserted-by":"publisher","first-page":"22999","DOI":"10.1021\/acsnano.3c08456","volume":"17","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang X, Campolo G, Teng X, Ying L, Edel JB, Ivanov AP. Single-molecule detection of \u03b1-synuclein oligomers in Parkinson\u2019s disease patients using nanopores. ACS Nano. 2023;17:22999\u20133009.","journal-title":"ACS Nano"},{"key":"900_CR434","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"ST Kumar","year":"2020","unstructured":"Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation-specific \u03b1-synuclein antibodies? Characterization and validation of 16 \u03b1-synuclein conformation-specific antibodies using well-characterized preparations of \u03b1-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis. 2020;146:105086.","journal-title":"Neurobiol Dis"},{"key":"900_CR435","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/nmeth947","volume":"3","author":"O S\u00f6derberg","year":"2006","unstructured":"S\u00f6derberg O, Gullberg M, Jarvius M, Ridderstr\u00e5le K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3:995\u20131000.","journal-title":"Nat Methods"},{"key":"900_CR436","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/brain\/awv040","volume":"138","author":"RF Roberts","year":"2015","unstructured":"Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson\u2019s disease brain. Brain. 2015;138:1642\u201357.","journal-title":"Brain"},{"key":"900_CR437","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/brain\/awaa008","volume":"143","author":"S Mazzetti","year":"2020","unstructured":"Mazzetti S, Basellini MJ, Ferri V, Cassani E, Cereda E, Paolini M, Calogero AM, Bolliri C, De Leonardis M, Sacilotto G, et al. \u03b1-synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson\u2019s disease. Brain. 2020;143:920\u201331.","journal-title":"Brain"},{"key":"900_CR438","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/jnr.24927","volume":"99","author":"A Behere","year":"2021","unstructured":"Behere A, Th\u00f6rnqvist PO, Winberg S, Ingelsson M, Bergstr\u00f6m J, Ekmark-Lew\u00e9n S. Visualization of early oligomeric \u03b1-synuclein pathology and its impact on the dopaminergic system in the (thy-1)-h[A30P]\u03b1-syn transgenic mouse model. J Neurosci Res. 2021;99:2525\u201339.","journal-title":"J Neurosci Res"},{"key":"900_CR439","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41531-024-00841-9","volume":"10","author":"NM Jensen","year":"2024","unstructured":"Jensen NM, Fu Y, Betzer C, Li H, Elfarrash S, Shaib AH, Krah D, Vitic Z, Reimer L, Gram H, et al. MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity. NPJ Parkinsons Dis. 2024;10:227.","journal-title":"NPJ Parkinsons Dis"},{"key":"900_CR440","doi-asserted-by":"publisher","first-page":"fcae193","DOI":"10.1093\/braincomms\/fcae193","volume":"6","author":"MT Tanaka","year":"2024","unstructured":"Tanaka MT, Miki Y, Mori F, Kon T, Furukawa T, Shimoyama S, Tatara Y, Ozaki T, Bettencourt C, Warner TT, Wakabayashi K. Intranasal administration of trehalose reduces \u03b1-synuclein oligomers and accelerates \u03b1-synuclein aggregation. Brain Commun. 2024;6:fcae193.","journal-title":"Brain Commun"},{"key":"900_CR441","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00401-025-02872-9","volume":"149","author":"H Sekiya","year":"2025","unstructured":"Sekiya H, Franke L, Hashimoto Y, Takata M, Nishida K, Futamura N, Hasegawa K, Kowa H, Ross OA, McLean PJ, et al. Widespread distribution of \u03b1-synuclein oligomers in LRRK2-related Parkinson\u2019s disease. Acta Neuropathol. 2025;149:42.","journal-title":"Acta Neuropathol"},{"key":"900_CR442","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00401-025-02871-w","volume":"149","author":"NM Jensen","year":"2025","unstructured":"Jensen NM, Vitic Z, Antorini MR, Viftrup TB, Parkkinen L, Jensen PH. Abundant non-inclusion \u03b1-synuclein pathology in Lewy body-negative LRRK2-mutant cases. Acta Neuropathol. 2025;149:41.","journal-title":"Acta Neuropathol"},{"key":"900_CR443","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG. Selkoe DJ. \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107\u201310.","journal-title":"Nature"},{"key":"900_CR444","doi-asserted-by":"publisher","first-page":"9596","DOI":"10.1073\/pnas.1505953112","volume":"112","author":"U Dettmer","year":"2015","unstructured":"Dettmer U, Newman AJ, von Saucken VE, Bartels T, Selkoe D. KTKEGV repeat motifs are key mediators of normal \u03b1-synuclein tetramerization: their mutation causes excess monomers and neurotoxicity. Proc Natl Acad Sci USA. 2015;112:9596\u2013601.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"900_CR445","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, et al. \u03b1-synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287:15345\u201364.","journal-title":"J Biol Chem"},{"key":"900_CR446","doi-asserted-by":"crossref","unstructured":"Miki Y, Tanji K, Shinnai K, Tanaka MT, Altay F, Foti SC, Strand C, Sasaki T, Kon T, Shimoyama S, et al. Pathological substrate of memory impairment in multiple system atrophy. Neuropathol Appl Neurobiol. 2022;e12844.","DOI":"10.1111\/nan.12844"},{"key":"900_CR447","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K, Futamura N, Kawamoto M, Kohara N, Dickson DW, et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease. Acta Neuropathol Commun. 2022;10:133.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR448","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","volume":"7","author":"MJ Park","year":"2011","unstructured":"Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson\u2019s disease. J Clin Neurol. 2011;7:215\u201322.","journal-title":"J Clin Neurol"},{"key":"900_CR449","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson\u2019s disease. Mov Disord. 2014;29:1019\u201327.","journal-title":"Mov disord"},{"key":"900_CR450","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol Neurodegener. 2016;11:7.","journal-title":"Mol NeurodeGener"},{"key":"900_CR451","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/mds.28611","volume":"36","author":"NK Majbour","year":"2021","unstructured":"Majbour NK, Abdi IY, Dakna M, Wicke T, Lang E, Ali Moussa HY, Thomas MA, Trenkwalder C, Safieh-Garabedian B, Tokuda T, et al. Cerebrospinal \u03b1-synuclein oligomers reflect disease motor severity in DeNoPa longitudinal cohort. Mov Disord. 2021;36:2048\u201356.","journal-title":"Mov disord"},{"key":"900_CR452","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41531-022-00330-x","volume":"8","author":"L Bl\u00f6meke","year":"2022","unstructured":"Bl\u00f6meke L, Pils M, Kraemer-Schulien V, Dybala A, Schaffrath A, Kulawik A, Rehn F, Cousin A, Nischwitz V, Willbold J, et al. Quantitative detection of \u03b1-Synuclein and tau oligomers and other aggregates by digital single particle counting. NPJ Parkinsons Dis. 2022;8:68.","journal-title":"NPJ Parkinsons Dis"},{"key":"900_CR453","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","volume":"6","author":"O Hansson","year":"2014","unstructured":"Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, N\u00e4gga K, Londos E, Varghese S, Majbour NK, et al. Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease. Alzheimers Res Ther. 2014;6:25.","journal-title":"Alzheimers Res Ther"},{"key":"900_CR454","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/mds.111","volume":"33","author":"van Steenoven I","year":"2018","unstructured":"van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier Wm, van de Berg Wdj, Teunissen CE, Lemstra AW. El-Agnaf OMA. \u03b1-synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies. Mov Disord. 2018;33:1724\u201333.","journal-title":"Mov disord"},{"key":"900_CR455","doi-asserted-by":"publisher","first-page":"e70374","DOI":"10.1002\/alz.70374","volume":"21","author":"H Sekiya","year":"2025","unstructured":"Sekiya H, Franke L, Ono D, DeTure M, Ross OA, Murray ME, McLean PJ, Ferman TJ, Dickson DW. Impact of hippocampal \u03b1-synuclein oligomers on cognitive trajectory in patients with dementia with Lewy bodies. Alzheimers Dement. 2025;21:e70374.","journal-title":"Alzheimers DeMent"},{"key":"900_CR456","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565\u201381.","journal-title":"Nat Rev Neurol"},{"key":"900_CR457","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0733-8619(05)70089-X","volume":"16","author":"JY Choi","year":"1998","unstructured":"Choi JY, Morris JC, Hsu CY. Aging and cerebrovascular disease. Neurol Clin. 1998;16:687\u2013711.","journal-title":"Neurol Clin"},{"key":"900_CR458","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s004010051197","volume":"100","author":"MZ Smith","year":"2000","unstructured":"Smith MZ, Nagy Z, Barnetson L, King EM, Esiri MM. Coexisting pathologies in the brain: influence of vascular disease and Parkinson\u2019s disease on Alzheimer\u2019s pathology in the hippocampus. Acta Neuropathol. 2000;100:87\u201394.","journal-title":"Acta Neuropathol"},{"key":"900_CR459","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-017-1709-7","volume":"134","author":"TL Spires-Jones","year":"2017","unstructured":"Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187\u2013205.","journal-title":"Acta Neuropathol"},{"key":"900_CR460","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181\u201393.","journal-title":"Brain"},{"key":"900_CR461","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32.","journal-title":"Mol NeurodeGener"},{"key":"900_CR462","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/mds.28011","volume":"35","author":"M Jecmenica Lukic","year":"2020","unstructured":"Jecmenica Lukic M, Kurz C, Respondek G, Grau-Rivera O, Compta Y, Gelpi E, Troakes C, van Swieten Jc, Giese A, Roeber S, et al. Copathology in progressive supranuclear palsy: does it matter? Mov Disord. 2020;35:984\u201393.","journal-title":"Mov disord"},{"key":"900_CR463","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/mds.29670","volume":"39","author":"H Sekiya","year":"2024","unstructured":"Sekiya H, Koga S, Murakami A, DeTure M, Ross OA, Uitti RJ, Cheshire WP, Wszolek ZK, Dickson DW. Frequency of comorbid pathologies and their clinical impact in multiple system atrophy. Mov Disord. 2024;39:380\u201390.","journal-title":"Mov disord"},{"key":"900_CR464","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"900_CR465","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"900_CR466","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National institute on aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"900_CR467","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1212\/WNL.56.12.1690","volume":"56","author":"T Polvikoski","year":"2001","unstructured":"Polvikoski T, Sulkava R, Myllykangas L, Notkola IL, Niinist\u00f6 L, Verkkoniemi A, Kainulainen K, Kontula K, P\u00e9rez-Tur J, Hardy J, Haltia M. Prevalence of Alzheimer\u2019s disease in very elderly people: a prospective neuropathological study. Neurology. 2001;56:1690\u201396.","journal-title":"Neurology"},{"key":"900_CR468","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2002.tb04794.x","volume":"977","author":"L White","year":"2002","unstructured":"White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann N Y Acad Sci. 2002;977:9\u201323.","journal-title":"Ann N Y Acad Sci"},{"key":"900_CR469","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaneurol.2022.5416","volume":"80","author":"F Grodstein","year":"2023","unstructured":"Grodstein F, Leurgans SE, Capuano AW, Schneider JA, Bennett DA. Trends in postmortem neurodegenerative and cerebrovascular neuropathologies over 25 years. JAMA Neurol. 2023;80:370\u201376.","journal-title":"JAMA Neurol"},{"key":"900_CR470","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005072-199710000-00002","volume":"56","author":"BT Hyman","year":"1997","unstructured":"Hyman BT, Trojanowski JQ. Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol & Exp Neurol. 1997;56:1095.","journal-title":"J Neuropathol & Exp Neurol"},{"key":"900_CR471","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","volume":"115","author":"KA Jellinger","year":"2008","unstructured":"Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115:427\u201336.","journal-title":"Acta Neuropathol"},{"key":"900_CR472","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181bacf9e","volume":"73","author":"PT Nelson","year":"2009","unstructured":"Nelson PT, Kryscio RJ, Jicha GA, Abner EL, Schmitt FA, Xu LO, Cooper G, Smith CD, Markesbery WR. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology. 2009;73:1127\u201333.","journal-title":"Neurology"},{"key":"900_CR473","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","volume":"69","author":"PT Kotzbauer","year":"2012","unstructured":"Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS. Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia. Arch Neurol. 2012;69:1326\u201331.","journal-title":"Arch Neurol"},{"key":"900_CR474","first-page":"216","volume":"76","author":"M Colom-Cadena","year":"2017","unstructured":"Colom-Cadena M, Grau-Rivera O, Planellas L, Cerquera C, Morenas E, Helgueta S, Mu\u00f1oz L, Kulisevsky J, Mart\u00ed MJ, Tolosa E, et al. Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol. 2017;76:216\u201324.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR475","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/bpa.12424","volume":"27","author":"KE McAleese","year":"2017","unstructured":"McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer\u2019s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27:472\u201379.","journal-title":"Brain Pathol"},{"key":"900_CR476","doi-asserted-by":"crossref","unstructured":"Tunold JA, Tan MMX, Koga S, Geut H, Rozemuller AJM, Valentino R, Sekiya H, Martin NB, Heckman MG, Bras J, et al. Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease. Brain. 2023.","DOI":"10.1093\/brain\/awad183"},{"key":"900_CR477","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0197-4580(97)00057-2","volume":"18","author":"The National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer\u2019s Disease","year":"1997","unstructured":"The National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer\u2019s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer\u2019s disease. Neurobiol Aging. 1997;18:S1\u20132.","journal-title":"Neurobiol Aging"},{"key":"900_CR478","doi-asserted-by":"publisher","first-page":"109120","DOI":"10.1016\/j.abb.2022.109120","volume":"717","author":"E Chau","year":"2022","unstructured":"Chau E, Kim JR. \u03b1-synuclein-assisted oligomerization of \u03b2-amyloid (1-42). Arch Biochem Biophys. 2022;717:109120.","journal-title":"Arch Biochem Biophys"},{"key":"900_CR479","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/acs.biochem.9b00655","volume":"59","author":"J Candreva","year":"2020","unstructured":"Candreva J, Chau E, Rice ME, Kim JR. Interactions between soluble species of \u03b2-amyloid and \u03b1-Synuclein promote oligomerization while inhibiting fibrillization. Biochemistry. 2020;59:425\u201335.","journal-title":"Biochemistry"},{"key":"900_CR480","doi-asserted-by":"publisher","first-page":"18276","DOI":"10.1021\/jacs.3c03212","volume":"145","author":"DM Vadukul","year":"2023","unstructured":"Vadukul DM, Papp M, Thrush RJ, Wang J, Jin Y, Arosio P, Aprile FA. \u03b1-Synuclein aggregation is triggered by oligomeric amyloid-\u03b2 42 via heterogeneous primary nucleation. J Am Chem Soc. 2023;145:18276\u201385.","journal-title":"J Am Chem Soc"},{"key":"900_CR481","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1471-4159.2012.07847.x","volume":"122","author":"K Ono","year":"2012","unstructured":"Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid \u03b2-protein and \u03b1-synuclein. J NeuroChem. 2012;122:883\u201390.","journal-title":"J NeuroChem"},{"key":"900_CR482","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1021\/acs.biochem.9b00215","volume":"58","author":"AKR Dasari","year":"2019","unstructured":"Dasari AKR, Kayed R, Wi S, Lim KH. Tau interacts with the C-Terminal region of \u03b1-Synuclein, promoting formation of toxic aggregates with distinct molecular conformations. Biochemistry. 2019;58:2814\u201321.","journal-title":"Biochemistry"},{"key":"900_CR483","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1074\/jbc.RA119.012284","volume":"295","author":"J Lu","year":"2020","unstructured":"Lu J, Zhang S, Ma X, Jia C, Liu Z, Huang C, Liu C, Li D. Structural basis of the interplay between \u03b1-synuclein and tau in regulating pathological amyloid aggregation. J Biol Chem. 2020;295:7470\u201380.","journal-title":"J Biol Chem"},{"key":"900_CR484","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/s41598-022-06846-9","volume":"12","author":"L Torres-Garcia","year":"2022","unstructured":"Torres-Garcia L, Jm PD, Brandi E, Haikal C, Mudannayake JM, Br\u00e1s IC, Gerhardt E, Li W, Svanbergsson A, Outeiro TF, et al. Monitoring the interactions between alpha-synuclein and Tau in vitro and in vivo using bimolecular fluorescence complementation. Sci Rep. 2022;12:2987.","journal-title":"Sci Rep"},{"key":"900_CR485","doi-asserted-by":"publisher","first-page":"e70053","DOI":"10.1111\/jnc.70053","volume":"169","author":"AL Fischer","year":"2025","unstructured":"Fischer AL, Schmitz M, Thom T, Zafar S, Younas N, da Silva Correia S, da Silva Correia A, Eyyuboglu SC, Zerr I. Alpha-synuclein demonstrates varying binding affinities with different tau isoforms. J NeuroChem. 2025;169:e70053.","journal-title":"J NeuroChem"},{"key":"900_CR486","doi-asserted-by":"publisher","first-page":"e26609","DOI":"10.1371\/journal.pone.0026609","volume":"6","author":"N Badiola","year":"2011","unstructured":"Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Gon\u00e7alves SA, Pera M, Su\u00e1rez-Calvet M, Clarimon J, Outeiro TF, Lle\u00f3 A. Tau enhances \u03b1-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One. 2011;6:e26609.","journal-title":"PLoS One"},{"key":"900_CR487","doi-asserted-by":"publisher","first-page":"15046","DOI":"10.1074\/jbc.M116.736355","volume":"291","author":"T Oikawa","year":"2016","unstructured":"Oikawa T, Nonaka T, Terada M, Tamaoka A, Hisanaga S, Hasegawa M. \u03b1-Synuclein fibrils exhibit gain of toxic function, promoting tau aggregation and inhibiting microtubule assembly. J Biol Chem. 2016;291:15046\u201356.","journal-title":"J Biol Chem"},{"key":"900_CR488","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.biopsych.2017.12.018","volume":"84","author":"DL Castillo-Carranza","year":"2018","unstructured":"Castillo-Carranza DL, Guerrero-Mu\u00f1oz MJ, Sengupta U, Gerson JE, Kayed R. \u03b1-Synuclein oligomers induce a unique toxic Tau Strain. Biol Psychiatry. 2018;84:499\u2013508.","journal-title":"Biol Psychiatry"},{"key":"900_CR489","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1038\/s41467-022-32350-9","volume":"13","author":"P Gracia","year":"2022","unstructured":"Gracia P, Polanco D, Taranc\u00f3n-D\u00edez J, Serra I, Bracci M, Oroz J, Laurents DV, Garc\u00eda I, Cremades N. Molecular mechanism for the synchronized electrostatic coacervation and co-aggregation of alpha-synuclein and tau. Nat Commun. 2022;13:4586.","journal-title":"Nat Commun"},{"key":"900_CR490","doi-asserted-by":"publisher","first-page":"108351","DOI":"10.1016\/j.jbc.2025.108351","volume":"301","author":"C Sun","year":"2025","unstructured":"Sun C, Zhou K, Pt D, Li C, Lee VMY, Zhou ZH, Peng C, Jiang L. Structural basis of a distinct \u03b1-synuclein strain that promotes tau inclusion in neurons. J Biol Chem. 2025;301:108351.","journal-title":"J Biol Chem"},{"key":"900_CR491","doi-asserted-by":"publisher","first-page":"1149036","DOI":"10.3389\/fnagi.2023.1149036","volume":"15","author":"H Wei","year":"2023","unstructured":"Wei H, Masurkar AV, Razavian N. On gaps of clinical diagnosis of dementia subtypes: a study of Alzheimer\u2019s disease and Lewy body disease. Front Aging Neurosci. 2023;15:1149036.","journal-title":"Front Aging neurosci"},{"key":"900_CR492","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009;23:295\u201397.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"900_CR493","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta Y, Parkkinen L, O\u2019Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, et al. Lewy- and alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important? Brain. 2011;134:1493\u2013505.","journal-title":"Brain"},{"key":"900_CR494","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00401-015-1526-9","volume":"131","author":"JB Toledo","year":"2016","unstructured":"Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, et al. Pathological \u03b1-synuclein distribution in subjects with coincident Alzheimer\u2019s and Lewy body pathology. Acta Neuropathol. 2016;131:393\u2013409.","journal-title":"Acta Neuropathol"},{"key":"900_CR495","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1212\/01.wnl.0000180964.60708.c2","volume":"65","author":"DK Johnson","year":"2005","unstructured":"Johnson DK, Morris JC, Galvin JE. Verbal and visuospatial deficits in dementia with Lewy bodies. Neurology. 2005;65:1232\u201338.","journal-title":"Neurology"},{"key":"900_CR496","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, McMillan CT, Wolk DA, Akhtar RS, Hurtig HI, et al. Cognitive and pathological influences of tau pathology in Lewy body disorders. Ann Neurol. 2019;85:259\u201371.","journal-title":"Ann Neurol"},{"key":"900_CR497","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/brain\/awab092","volume":"144","author":"PA Boyle","year":"2021","unstructured":"Boyle PA, Wang T, Yu L, Wilson RS, Dawe R, Arfanakis K, Schneider JA, Bennett DA. To what degree is late life cognitive decline driven by age-related neuropathologies? Brain. 2021;144:2166\u201375.","journal-title":"Brain"},{"key":"900_CR498","doi-asserted-by":"publisher","first-page":"e0217566","DOI":"10.1371\/journal.pone.0217566","volume":"14","author":"M Malek-Ahmadi","year":"2019","unstructured":"Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, et al. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS One. 2019;14:e0217566.","journal-title":"PLoS One"},{"key":"900_CR499","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jnnp-2020-322983","volume":"92","author":"de Boer Emj","year":"2020","unstructured":"de Boer Emj, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P, van den Bos M, Halliday GM, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92:86\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"900_CR500","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602\u201311.","journal-title":"Biochem Biophys Res Commun"},{"key":"900_CR501","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130\u201333.","journal-title":"Science"},{"key":"900_CR502","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3233\/JAD-132351","volume":"42","author":"HA Keage","year":"2014","unstructured":"Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR, Highley JR, Dening T, Brayne C. TDP-43 pathology in the population: prevalence and associations with dementia and age. J Alzheimers Dis. 2014;42:641\u201350.","journal-title":"J Alzheimers Dis"},{"key":"900_CR503","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain. 2016;139:2983\u201393.","journal-title":"Brain"},{"key":"900_CR504","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3233\/JAD-180162","volume":"66","author":"ME Flanagan","year":"2018","unstructured":"Flanagan ME, Cholerton B, Latimer CS, Hemmy LS, Edland SD, Montine KS, White LR, Montine TJ. TDP-43 neuropathologic associations in the Nun study and the Honolulu-asia Aging study. J Alzheimers Dis. 2018;66:1549\u201358.","journal-title":"J Alzheimers Dis"},{"key":"900_CR505","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/brain\/awae212","volume":"148","author":"E Mikhailenko","year":"2025","unstructured":"Mikhailenko E, Colangelo K, Tuimala J, Kero M, Savola S, Raunio A, Kok EH, Tanskanen M, M\u00e4kel\u00e4 M, Puttonen H, et al. Limbic-predominant age-related TDP-43 encephalopathy in the oldest old: a population-based study. Brain. 2025;148:154\u201367.","journal-title":"Brain"},{"key":"900_CR506","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00401-007-0261-2","volume":"114","author":"H Nakashima-Yasuda","year":"2007","unstructured":"Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221\u201329.","journal-title":"Acta Neuropathol"},{"key":"900_CR507","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.brainres.2007.09.048","volume":"1184","author":"S Higashi","year":"2007","unstructured":"Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer\u2019s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284\u201394.","journal-title":"Brain Res"},{"key":"900_CR508","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00401-008-0480-1","volume":"117","author":"T Arai","year":"2009","unstructured":"Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H. Phosphorylated TDP-43 in Alzheimer\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:125\u201336.","journal-title":"Acta Neuropathol"},{"key":"900_CR509","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13024-021-00503-x","volume":"16","author":"A Meneses","year":"2021","unstructured":"Meneses A, Koga S, O\u2019Leary J, Dickson DW, Bu G, Zhao N. TDP-43 pathology in Alzheimer\u2019s disease. Mol Neurodegener. 2021;16:84.","journal-title":"Mol NeurodeGener"},{"key":"900_CR510","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ana.21425","volume":"64","author":"M Hasegawa","year":"2008","unstructured":"Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60\u201370.","journal-title":"Ann Neurol"},{"key":"900_CR511","doi-asserted-by":"crossref","unstructured":"Murakami A, Koga S, Sekiya H, Oskarsson B, Boylan K, Petrucelli L, Josephs KA, Dickson DW. Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology. Brain Pathol. 2022;e13100.","DOI":"10.1111\/bpa.13100"},{"key":"900_CR512","doi-asserted-by":"crossref","unstructured":"Jamerlan AM. An SSA. A microplate-based approach to map interactions between TDP-43 and \u03b1-synuclein. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11030573"},{"key":"900_CR513","doi-asserted-by":"publisher","first-page":"166953","DOI":"10.1016\/j.jmb.2021.166953","volume":"433","author":"S Dhakal","year":"2021","unstructured":"Dhakal S, Wyant CE, George HE, Morgan SE, Rangachari V. Prion-like C-Terminal Domain of TDP-43 and \u03b1-Synuclein interact synergistically to generate neurotoxic hybrid fibrils. J Mol Biol. 2021;433:166953.","journal-title":"J Mol Biol"},{"key":"900_CR514","doi-asserted-by":"publisher","first-page":"102498","DOI":"10.1016\/j.jbc.2022.102498","volume":"298","author":"S Dhakal","year":"2022","unstructured":"Dhakal S, Robang AS, Bhatt N, Puangmalai N, Fung L, Kayed R, Paravastu AK, Rangachari V. Distinct neurotoxic TDP-43 fibril polymorphs are generated by heterotypic interactions with \u03b1-synuclein. J Biol Chem. 2022;298:102498.","journal-title":"J Biol Chem"},{"key":"900_CR515","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1007\/s00415-020-09718-2","volume":"267","author":"M Buciuc","year":"2020","unstructured":"Buciuc M, Whitwell JL, Boeve BF, Ferman TJ, Graff-Radford J, Savica R, Kantarci K, Fields JA, Knopman DS, Petersen RC, et al. TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional\/diffuse Lewy body disease. J Neurol. 2020;267:1444\u201353.","journal-title":"J Neurol"},{"key":"900_CR516","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, et al. TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathol. 2014;127:811\u201324.","journal-title":"Acta Neuropathol"},{"key":"900_CR517","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-021-02383-3","volume":"143","author":"MT Uemura","year":"2022","unstructured":"Uemura MT, Robinson JL, Cousins KAQ, Tropea TF, Kargilis DC, McBride JD, Suh E, Xie SX, Xu Y, Porta S, et al. Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathol. 2022;143:15\u201331.","journal-title":"Acta Neuropathol"},{"key":"900_CR518","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","volume":"386","author":"JT O\u2019Brien","year":"2015","unstructured":"O\u2019Brien JT. Thomas A. Vascular dementia. Lancet. 2015;386:1698\u2013706.","journal-title":"Lancet"},{"key":"900_CR519","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-023-00640-5","volume":"18","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Shue F, Bu G, Kanekiyo T. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer\u2019s disease. Mol Neurodegener. 2023;18:46.","journal-title":"Mol NeurodeGener"},{"key":"900_CR520","doi-asserted-by":"crossref","unstructured":"Dupr\u00e9 N, Drieu A, Joutel A. Pathophysiology of cerebral small vessel disease: a journey through recent discoveries. J Clin Invest 2024;134.","DOI":"10.1172\/JCI172841"},{"key":"900_CR521","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1440-1789.2006.00699.x","volume":"26","author":"D Isojima","year":"2006","unstructured":"Isojima D, Togo T, Kosaka K, Fujishiro H, Akatsu H, Katsuse O, Iritani S, Matsumoto T, Hirayasu Y. Vascular complications in dementia with Lewy bodies: a postmortem study. Neuropathology. 2006;26:293\u201397.","journal-title":"Neuropathology"},{"key":"900_CR522","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00401-003-0676-3","volume":"105","author":"KA Jellinger","year":"2003","unstructured":"Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson\u2019s disease. A postmortem study. Acta Neuropathol. 2003;105:415\u201319.","journal-title":"Acta Neuropathol"},{"key":"900_CR523","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/NEN.0b013e3181d88e63","volume":"69","author":"E Ghebremedhin","year":"2010","unstructured":"Ghebremedhin E, Rosenberger A, R\u00fcb U, Vuksic M, Berhe T, Bickeb\u00f6ller H, de Vos RA, Thal DR, Deller T. Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J Neuropathol Exp Neurol. 2010;69:442\u201348.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR524","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/jnen\/62.12.1287","volume":"62","author":"DR Thal","year":"2003","unstructured":"Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis\/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol. 2003;62:1287\u2013301.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR525","doi-asserted-by":"crossref","unstructured":"Chen ZC, Gan J, Yang Y, Meng Q, Han J, Ji Y. The vascular risk factors and vascular neuropathology in subjects with autopsy-confirmed dementia with Lewy bodies. Int J Geriatr Psychiatry. 2022;37.","DOI":"10.1002\/gps.5683"},{"key":"900_CR526","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1212\/WNL.0000000000207497","volume":"101","author":"S Agrawal","year":"2023","unstructured":"Agrawal S, Leurgans SE, Nag S, Oveisgharan S, Barnes LL, Bennett DA, Buchman AS, Schneider JA. Effects of cerebrovascular and Lewy body pathology on parkinsonian signs in community-dwelling older adults. Neurology. 2023;101:e754\u201363.","journal-title":"Neurology"},{"key":"900_CR527","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/bpa.12769","volume":"30","author":"Y Hase","year":"2020","unstructured":"Hase Y, Polvikoski TM, Firbank MJ, Craggs LJL, Hawthorne E, Platten C, Stevenson W, Deramecourt V, Ballard C, Kenny RA, et al. Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. Brain Pathol. 2020;30:191\u2013202.","journal-title":"Brain Pathol"},{"key":"900_CR528","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-008-0366-2","volume":"115","author":"DR Thal","year":"2008","unstructured":"Thal DR, Griffin WS, de Vos RA. Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer\u2019s disease. Acta Neuropathol. 2008;115:599\u2013609.","journal-title":"Acta Neuropathol"},{"key":"900_CR529","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1749-6632.2000.tb06404.x","volume":"903","author":"JH Xuereb","year":"2000","unstructured":"Xuereb JH, Brayne C, Dufouil C, Gertz H, Wischik C, Harrington C, Mukaetova-Ladinska E, McGee MA, O\u2019Sullivan A, O\u2019Connor D, et al. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci. 2000;903:490\u201396.","journal-title":"Ann N Y Acad Sci"},{"key":"900_CR530","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1212\/WNL.58.11.1629","volume":"58","author":"LA Pfeifer","year":"2002","unstructured":"Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002;58:1629\u201334.","journal-title":"Neurology"},{"key":"900_CR531","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/WNL.0000000000002175","volume":"85","author":"PA Boyle","year":"2015","unstructured":"Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology. 2015;85:1930\u201336.","journal-title":"Neurology"},{"key":"900_CR532","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/JAD-150241","volume":"49","author":"M M\u00e4kel\u00e4","year":"2016","unstructured":"M\u00e4kel\u00e4 M, Paetau A, Polvikoski T, Myllykangas L, Tanskanen M. Capillary amyloid-\u03b2 protein deposition in a population-based study (vantaa 85+). J Alzheimers Dis. 2016;49:149\u201357.","journal-title":"J Alzheimers Dis"},{"key":"900_CR533","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jnen\/62.9.885","volume":"62","author":"T Revesz","year":"2003","unstructured":"Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol. 2003;62:885\u201398.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR534","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.410300503","volume":"30","author":"JP Vonsattel","year":"1991","unstructured":"Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637\u201349.","journal-title":"Ann Neurol"},{"key":"900_CR535","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnen\/61.3.282","volume":"61","author":"DR Thal","year":"2002","unstructured":"Thal DR, Ghebremedhin E, R\u00fcb U, Yamaguchi H, Del Tredici K, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:282\u201393.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR536","first-page":"19","volume":"3","author":"S Love","year":"2014","unstructured":"Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, Yamada M, McCarron M, Minett T, Matthews F, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014;3:19\u201332.","journal-title":"Am J Neurodegener Dis"},{"key":"900_CR537","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1750-3639.1998.tb00161.x","volume":"8","author":"KA Jellinger","year":"1998","unstructured":"Jellinger KA. Dementia with grains (argyrophilic grain disease). Brain Pathol. 1998;8:377\u201386.","journal-title":"Brain Pathol"},{"key":"900_CR538","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/brain\/awm305","volume":"131","author":"I Ferrer","year":"2008","unstructured":"Ferrer I, Santpere G, van Leeuwen FW. Argyrophilic grain disease. Brain. 2008;131:1416\u201332.","journal-title":"Brain"},{"key":"900_CR539","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neurobiolaging.2006.10.032","volume":"29","author":"KA Josephs","year":"2008","unstructured":"Josephs KA, Whitwell JL, Parisi JE, Knopman DS, Boeve BF, Geda YE, Jack CR Jr., Petersen RC, Dickson DW. Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol Aging. 2008;29:566\u201373.","journal-title":"Neurobiol Aging"},{"key":"900_CR540","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s40478-024-01828-6","volume":"12","author":"O Yokota","year":"2024","unstructured":"Yokota O, Miki T, Nakashima-Yasuda H, Ishizu H, Haraguchi T, Ikeda C, Hasegawa M, Miyashita A, Ikeuchi T, Nishikawa N, et al. Pure argyrophilic grain disease revisited: independent effects on limbic, neocortical, and striato-pallido-nigral degeneration and the development of dementia in a series with a low to moderate Braak stage. Acta Neuropathol Commun. 2024;12:121.","journal-title":"Acta Neuropathol Commun"},{"key":"900_CR541","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s004010050642","volume":"93","author":"M Tolnay","year":"1997","unstructured":"Tolnay M, Spillantini MG, Goedert M, Ulrich J, Langui D, Probst A. Argyrophilic grain disease: widespread hyperphosphorylation of tau protein in limbic neurons. Acta Neuropathol. 1997;93:477\u201384.","journal-title":"Acta Neuropathol"},{"key":"900_CR542","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00005072-199702000-00006","volume":"56","author":"P Martinez-Lage","year":"1997","unstructured":"Martinez-Lage P, Munoz DG. Prevalence and disease associations of argyrophilic grains of Braak. J Neuropathol Exp Neurol. 1997;56:157\u201364.","journal-title":"J Neuropathol Exp Neurol"},{"key":"900_CR543","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s007020050096","volume":"105","author":"H Braak","year":"1998","unstructured":"Braak H, Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm (Vienna). 1998;105:801\u201319.","journal-title":"J Neural Transm (Vienna)"},{"key":"900_CR544","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2990.1989.tb01146.x","volume":"15","author":"H Braak","year":"1989","unstructured":"Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl neurobiol. 1989;15:13\u201326.","journal-title":"Neuropathol Appl neurobiol"},{"key":"900_CR545","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00401-002-0644-3","volume":"105","author":"E Iseki","year":"2003","unstructured":"Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K. Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol. 2003;105:265\u201370.","journal-title":"Acta Neuropathol"},{"key":"900_CR546","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/WAD.0b013e318199d833","volume":"23","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord. 2009;23:229\u201333.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"900_CR547","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/neup.12208","volume":"35","author":"T Homma","year":"2015","unstructured":"Homma T, Mochizuki Y, Takahashi K, Komori T. Medial temporal regional argyrophilic grain as a possible important factor affecting dementia in Parkinson\u2019s disease. Neuropathology. 2015;35:441\u201351.","journal-title":"Neuropathology"},{"key":"900_CR548","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jnen\/63.9.911","volume":"63","author":"Y Saito","year":"2004","unstructured":"Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63:911\u201318.","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00900-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:04:29Z","timestamp":1762171469000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00900-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":548,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00900-6","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}